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 Acinetobacter baumannii is a Gram-negative, nosocomial pathogen that typically 
infects immune-compromised individuals. It is of growing concern in healthcare settings 
due to its ability to form biofilms, survive long periods of desiccation, and easily acquire 
antibiotic resistance. In an effort to better combat this pathogen, we have focused on 
elucidating aspects of the pathogenesis of A. baumannii. Many Gram-negative bacteria 
such as Vibrio cholerae and Pseudomonas aeruginosa possess a Type II Secretion 
System (T2SS) to secrete substrates used for colonization and survival in their 
environment. In our first study, we highlighted the unique organization of the T2SS 
genes, gsp, in A. baumannii and demonstrated that, despite this uniqueness, the T2SS 
is functional by analyzing a secreted lipase, LipA. Unlike the wild-type ATCC 17978 
strain, both the ΔlipA and ΔgspD mutant strains were unable to grow on media where 
long-chain fatty acids were the only source of nutrients. This difference was also 
observed in a quantitative lipase assay using 4-nitrophenyl myristate as the substrate 
for LipA. To determine if the T2SS has a role in vivo we inoculated mice via tail vein with 
an equal number of the wild-type 17978 strain and a mutant strain (either the ΔlipA or 
ΔgspD strain). Both mutants were outcompeted by the wild-type strain indicating that the 
T2SS is necessary for full colonization in a bacteremia model. 
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We continued exploring the role of the T2SSs in pathogenesis by characterizing 
the metalloprotease CpaA secreted by the A. baumannii strain AB031. We verified that 
CpaA is a T2S substrate using an Activated Partial Thromboplastin Time (aPTT) assay, 
which measures the function of the intrinsic coagulation pathway, the target of CpaA. A 
modified aPTT assay demonstrated that CpaA targets the coagulation component factor 
XII (fXII). We pinpointed the site of cleavage between Pro308 and Thr309 by subjecting 
cleaved fXII to N-terminal sequencing by Edman degradation. As Thr309 is O-
glycosylated, we tested for the necessity of O-glycosylated residues by treating fXII with 
deglycosylases. CpaA was unable to cleave deglycosylated fXII, but deglycosylation did 
not affect the function of fXII when measured by an aPTT assay. Finally, we utilized a 
murine bacteremia model and observed that the strain lacking CpaA was unable to 
compete with the wild-type strain, suggesting that it contributes to in vivo fitness 
possibly by preventing intravascular capture by the coagulation system. 
 In addition to the virulence traits mentioned above, the T2SS also aids in survival 
in serum as the wild-type strain, 17978, withstands complement mediated killing via the 
alternative complement pathway significantly better than a T2SS mutant. As the T2SS 
contributes to in vivo survival and protection from human complement, we designed, 
optimized, and validated a high-throughput screen (HTS) to identify inhibitors of the 
T2SS in A. baumannii. By targeting the T2SS a putative inhibitor would block the 
secreted substrates and, thereby, their functions. By utilizing a whole-cell lipase assay, 
we developed a HTS with low variation among the controls and a dynamic range 
between the positive and negative controls, giving a z-factor of 0.65. In addition, we 
showed that our screen is robust, sensitive, and reproducible. Taken together, my thesis 
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work provides much needed insight into the pathogenesis of A. baumannii by 




Chapter I:  
Introduction 
Acinetobacter baumannii Infection 
Acinetobacter baumannii is a Gram-negative, global nosocomial pathogen that 
has developed multi-drug resistance (1-3). Several risk factors increase the chance of 
developing an A. baumannii infection, including but not limited to admission to the ICU, 
having invasive devices or extensive wounds, or having recently taken antibiotics (4-6). 
While A. baumannii has a reputation as a nosocomial pathogen that only targets the 
immune-compromised, this may no longer be the case. Recently isolated, highly virulent 
strains have caused fatal infections in patients with relatively low co-morbidity, and 
illness scores and these strains are capable of killing mice without compromising the 
immune system prior to infection (7, 8) . A. baumannii causes pneumonia, bacteremia, 
meningitis, urinary tract infection, and skin and wound infection that may lead to sepsis 
(6, 9). In addition to causing clinical symptoms, A. baumannii can survive long periods 
of desiccation, and this persistence can lead to easy transmission of the disease from 
contaminated tubing, bed rails, bedding, and sinks (10). Understanding how A. 





A. baumannii is one of the ESKAPE pathogens, along with the pathogens 
Enterococcus faecalis, methicillin-resistant Staphlyococcus aureus, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, and Enterbacter species (11). These 
pathogens are concerning not only because they cause the bulk of nosocomial 
infections in the United States, but also because they are either highly pathogenic, 
highly antibiotic-resistant, or both (11). Antibiotic resistant strains of A. baumannii have 
surged, due in part to its ability to acquire DNA through natural transformation (12). 
When nosocomial infections of A. baumannii were first identified, they were easily 
treated with antibiotics. Recently, many multi-drug resistant strains, which are resistant 
to at least three classes of antibiotics, have been isolated as well as pan-resistant 
strains which are resistant to at least one member of all known antibiotic classes (6, 13).  
At sub-minimal inhibitory concentrations (MIC), antibiotics are unable to stop a 
bacterial infection. Moreover, antibiotic use results in an increase in bacterial 
exopolysaccharide production and a concomitant increase in resistance to some 
classes of antibiotics (14). In addition, increased capsule production also confers 
resistance to complement-mediated killing in serum (14). This two-pronged effect is 
especially troubling given the dual problem of over-prescription of antibiotics and the 
lack of compliance with taking a full antibiotic regimen. 
To prevent antibiotics from even reaching their target, A. baumannii has ways to 
remove the antibiotics or block their entry. Efflux pumps can actively remove antibiotics 
from the cells. Resistant nodulation cell division efflux pumps are upregulated in many 
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multi-drug resistant strains of A. baumannii. Overexpression of these pumps does come 
with a small fitness cost, most likely due to the increase of energy needed, but also 
increases virulence (15).  Acylation of lipid A of A. baumannii lipopolysaccharide by the 
LpxM-dependent acylation system is important for resistance to vertebrate cationic 
antimicrobial peptides (CAMPs) as well as to polymyxins B and E (16) as it prevents the 
antibiotics from even reaching the cell membrane. These are just two of the possible 
methods for preventing antibiotic access. 
When antibiotics are administered in high enough dosage to enter and damage 
the bacterium, A. baumannii has additional systems to protect itself. The protein RecA, 
which repairs DNA damage, plays a protective role against some antibiotics. For 
example, a recA mutant of A. baumannii is more sensitive to β-lactams, colistin, 
trimethoprim-sulfamethoxazole, and quinolone-type antibiotics (17). 
In some cases, the acquisition of colistin resistance can lead to a loss of 
virulence, such as when there is a mutation in the lpxACD genes (18). However, a 
mutation in a different gene, pmrB, increases colistin resistance without a loss of 
virulence (18). Like many bacteria, A. baumannii develops and uses a wide variety of 
mechanisms to survive antibiotic treatment. The mechanisms by which A. baumannii is 
killed by antimicrobials are diverse, and work continues in this area to guide further 
treatment options as well as to limit the occurrence of resistant strains. 
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Mechanisms of Pathogenesis 
The symptoms of some bacterial infections can sometimes be attributed to one 
or a few toxins or virulence factors. Examples of this include the cholera toxin produced 
by Vibrio cholerae or toxin A and toxin B from Clostridium difficile. However, this is not 
the case with A. baumannii. Despite the growing body of work on A. baumannii 
pathogenesis, no one factor nor even a small subset of factors has been found to be 
solely responsible for the clinical outcomes of the disease. However, strains with 
increased virulence have been isolated recently, and, while they need further 
investigation, it is possible that they may have acquired new gene(s) that contribute to 
virulence.  
One of the main contributions to pathogenesis of A. baumannii is the bacterium’s 
ability to persist on surfaces and survive desiccation for long periods. The RecA protein 
mentioned earlier (which aids in DNA repair) increases bacterial survival in dry 
conditions, as it repairs the damage caused by desiccation (17). Acylation of lipid A is 
also implicated in protection from desiccation, as loss of fatty acids in the outer 
membrane due to a lack of the glycotransferase LpxM leads to a decrease in survival in 
dry conditions (16). Biofilms also increase A. baumannii’s persistence on surfaces (19), 
and in fact, may be one of the main contributions to its survival. The sensor kinases 
BfmR (20) and GacS (21) control formation of biofilms. Production of the biofilm 
depends on pili which are assembled by the chaperone-usher system (CsuABCDE) (22) 
and the biofilm-associated protein (BAP) (23). In addition, a four gene locus, pgaABCD, 
encodes enzymes required for the synthesis of poly-beta-1-6-N-acetylglucosamine, an 
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extracellular polysaccharide that forms the biofilm matrix and supports the typical three-
dimensional architecture of biofilm (24). A general O-linked glycosylation system 
encoded by pglL is required for the glycosylation of several membrane proteins. PglL is 
an O-oligosaccharyltransferases, and pglL mutant strains make less biofilms, are less 
virulent in the Dictyostelium discoideum and Galleria mellonella models of infection, and 
are less competitive in BALB/c mice when compared to the wild-type (25). 
Understanding more about how A. baumannii produces and maintains its biofilms may 
reveal new strategies for controlling its spread in hospital settings. 
In addition to surviving on surfaces, many strains of A. baumannii survive in 
serum and withstand complement-mediated killing. Part of this resilience is due to 
capsular polysaccharides (26). The genes in the sequence variable cluster or K locus 
determine which polysaccharides are displayed on the surface, thus affecting capsule 
composition and structure (14, 26). An additional mechanism may be the production of 
a plasminogen binding protein, CipA. Once bound to CipA, the plasminogen degrades 
fibrinogen and the complement protein C3b (27). Lack of CipA decreases survival in 
serum, specifically through the alternative complement pathway (27). Additional 
mechanisms include cell-surface binding of Factor H (28, 29) and complement 
inactivation by the serine protease PKF (30). Another contributor to growth in serum is 
phospholipase D (PLD) (31). There are three different genes which code for PLD, and, 
in addition to supporting growth in serum, they appear to work in concert for epithelial 
cell invasion (32). Phospholipase C (PLC) and PLD are also important in iron 
acquisition. By cleaving the phospholipids in host membranes, the phospholipases 
initiate cytolysis of the host cells. The release of host intracellular contents after lysis 
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can release iron (33). This lysis can be membrane specific. For example, A. baumannii 
is able to lyse sheep, human, and horse erythrocytes but to varying degrees. The 
abundance of erythrocyte phosphatidylcholine present in the membrane is positively 
correlated with cell lysis (34). The combination of all these proteins and systems 
supports the survival of A. baumannii in a hostile environment and allow it to colonize. 
Another route of survival is to affect the host cells using outer membrane vesicles 
(OMV). OMVs are used as delivery vehicles that transport effector proteins to host cells, 
allowing for interaction between the bacterium and the host cell without close physical 
contact. The OMVs of A. baumannii contain a wide variety of effectors, including OmpA, 
proteases, phospholipases, superoxide dismutase, and catalase (35). OmpA, a porin, is 
necessary for bronchial epithelial cell invasion and cytotoxicity (36, 37). Another OMV 
protein, a porin Omp 33-36, also induces cytotoxicity by activating caspases which lead 
to autophagy of the mammalian cell (38). This cytotoxic effect could be targeting cells 
like macrophages as a mechanism to evade the immune system (38). A. baumannii 
OMVs also induce an inflammatory response by upregulating cytokine genes in the lung 
after intratracheal injection of OMVs (39). While OMVs are not unique to A. baumannii, 
they do provide a vast amount of benefits to the bacterium. 
Like other pathogenic bacteria, A. baumannii must possess a way to thrive in the 
human body where there is a lack of free iron (40). One strategy is to produce a 
siderophore, acinetobactin (41, 42). While many strains do have the genes to produce 
this siderophore, others are able to acquire iron without it, suggesting that A. baumannii 
strains possess and utilize different iron-acquisition pathways (43, 44). Another possible 
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method of iron acquisition is the formation of iron-sulfur (Fe-S) proteins, which can store 
iron and thereby act as an iron pool. Eukaryotes and prokaryotes have developed 
systems to regulate the formation of such proteins, as spontaneous formation would 
only occur under toxic levels of iron and sulfur. Fe-S proteins are necessary for A. 
baumannii survival; lack of one of the scaffold Fe-S proteins, NfuA, results in an inability 
to persist in human epithelial cells and the inability to kill Galleria mellonella larvae (45). 
Just as free iron is tightly controlled in the human body but highly necessary for 
bacterial survival, so are other transition metals such as zinc and manganese. While no 
mechanism for manganese acquisition has been discovered to date, a zinc-acquisition 
system called Znu has been identified in A. baumannii (46). This system is an ABC 
transporter and is required for full colonization of the lung in a murine pulmonary model 
of infection wherein mutant strains are outcompeted by the wild-type strain (46). By 
deploying systems to acquire metals, A. baumannii is more competitive in a nutrient-
deficient environment. 
While there is a plethora of virulence and colonization factors described in A. 
baumannii, we still do not have a complete understanding of its pathogenesis. Thus, we 
are at a great disadvantage when it comes to treating outbreaks and designing 
therapeutics for antibiotic resistant A. baumannii as we are still missing the full picture. 
Type II Secretion System 
Many Gram-negative bacteria transport virulence factors across the cell envelope 
using secretion systems, such as the Type II Secretion System (T2SS). One of seven 
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protein secretion systems used by Gram-negative bacteria (47), the T2SS is most 
commonly found among members of the Proteobacteria, including Vibrio cholerae, 
Enterotoxigenic and Enterohemorrhagic Escherichia coli, Pseudomonas aeruginosa and 
Legionella pneumophila (48, 49) (50). The T2SS is a multiprotein complex that is 
responsible for extracellular secretion of toxins, proteases, lipases, and enzymes that 
break down complex carbohydrates (a small subset of these are shown in Table 1.1). It 
is encoded by between 12 to 16 general secretion pathway (gsp) genes (Figure 1.1) 
(48, 49, 51) and spans the inner and outer membranes.  
The gsp genes are named gspA through gspO and gspS, with gspC though 
gspM being essential for T2S. While many of the bacterial species that carry the T2S 
genes use the gsp notation, there are some deviations such as eps in V. cholerae and 
xcp in P. aeruginosa. If any of the genes are missing, the secretion apparatus is no 
longer functional (52).  
The inner platform of the secretion apparatus is composed of GspE, GspF, GspL, 
and GspM (53). GspE is the secretion ATPase, which powers the secretion apparatus 
and resides in the cytoplasm (54, 55). GspE is attached to this platform via interaction of 
its N-terminus with GspL (55, 56). GspL and GspM stabilize each other and protect 
each other from degradation (57). GspL also interacts with the major pseudopilin, 
GspG, and may serve as the means to transport energy from the ATPase to the 
pseudopilus (58). The last member of this platform is GspF, which, like the other 
members, plays a role in stabilization (53). 
9 
 
GspC is anchored to the inner membrane and exposed to the periplasmic space. 
Studies have demonstrated an interaction between GspC and the outer membrane 
porin, GspD (59). GspC has two important structural domains: the PDZ domain and 
homology region (60). The PDZ domain in GspC and the N-terminal domain of GspD 
are important determinants for T2S substrate specificity (61, 62). While the PDZ domain 
is necessary for secretion of some proteins, it is not necessary for all. Some GspC have 
a coil-coiled domain in place of the PDZ domain which plays a similar role as the PDZ 
domain (63). The homology region interacts directly with GspD. GspD forms the gated 






Figure 1.1. A schematic representation of the T2S System in A. baumannii. The T2S apparatus 
spans the inner membrane, periplasm, and outer membrane. T2S substrates (indicated by S) are 
transported through the Sec or Tat system, fold in the periplasm, and are secreted out through the outer 
membrane porin (GspD). Once secreted, the substrates may be cell-associated or fully secreted. GspG, 
H, I, J, and K form the pseudopilus while GspC, M, L, and F make up the inner platform. GspE is an 
ATPase, which powers the system. S, substrate. 
GspG, H, I, J, and K make up the pseudopilus, so named because it is not 
present on the bacterial surface but is similar to the Type IV pilus (Figure 1.1). GspG is 
called the major pilin as it is the most abundant of the pilins while GspH, I, J, and K are 
the minor pilins. The prepilin peptidase, GspO, is responsible for the maturation of the 
pseudopilins by cleavage and methylation(65). GspI has been implicated in initiation of 
pseudopilus assembly, as there is a reduction in the number of pili in a gspI mutant (66). 
GspK is localized to the tip of the pseudopilus (67). It is not currently known how the 

























like model that envisions the pseudopilus forming to push a substrate out of the outer 
porin and then retracting to pick up the next substrate (67). However, unlike in the 
similarly constructed Type IVa pilus, there is no retraction ATPase for the T2S, so the 
question of how the piston would retract remains to be answered. Studies have shown 
that GspK destabilizes GspG and could cause the pseudopilus to degrade, which could 
explain how the pseudopilus separates from GspD (66). However, this mechanism 
would necessitate reassembly of the pseudopilus for every substrate. Another theory is 
an Archimedes screw-like model wherein substrates continually attach to the 
pseudopilus for transport to GspD on an ever present escalator (68).  
Proteins that are T2S substrates have an N-terminal signal sequence that targets 
them to either the Sec or Tat export systems (69). Once in the periplasmic space, the 
proteins fold and interact with GspC, GspD, and the pseudopilus, suggesting that the 
substrates are recruited by GspC. The exact mechanism of this recruitment is unknown. 
However, a study using the T2S substrate PulA from K. oxytoca showed that a three 
dimensional structural motif may be required for secretion, indicating that identification 
of a T2S signal may require an evaluation of structural motifs in the folded protein rather 
than amino acid sequences alone (70). Regardless of the exact recruitment mechanism, 
the substrates then bind to the pseudopilus and are secreted out through GspD (63).  
Four additional Gsp proteins are present in some but not all bacteria with a 
T2SS: GspA, B, N, and S. GspA and GspB aid in the assembly of the secretin. 
However, even in bacterial species where they are present, they may not be required 
for secretion, suggesting they may have a redundant role in those species or they may 
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only be required under certain growth conditions (71). Similarly, GspN also binds to 
GspD and may play a role in stabilization. Just as with GspA and B, it is also not 
required for secretion in all the bacterial species where it is present (72). GspS is a 
lipoprotein which is located in the outer membrane and aids in the insertion and 
stabilization of GspD (73, 74).  These four proteins may play more species specific roles 
rather than global T2S roles. 
Table 1.1. Examples of T2S system substrates. 
Bacterial Species Substrates References 
V. cholerae Cholera Toxin, Serine proteases, 
Lipase 
(49, 75, 76)  
E. coli (ETEC) Metalloprotease, Heat-labile toxin (77, 78)  
E. coli (EPEC) Lipoprotein (79)  
E. coli (EHEC) Metalloprotease (80)  
Pseudomonas aeruginosa Lipases, Alkaline Phosphatase (81, 82)  
Klebsiella oxytoca Pullulanase (83)  
Legionella pneumophila RNase, lipase, phospholipase, 
chitinase 
(84, 85)  
Host Response to Bacterial Infections 
 Just as bacteria have evolved many mechanisms, such as secretion systems, to 
survive in their respective environments, the host has also developed systems to detect 
and destroy bacteria. While a full discussion of the interaction between bacteria and the 
host is outside the scope of this dissertation, I will provide some examples. Bacteria 
must get past innate immune defenses, including breaching physical barriers. Many 
immune cells have pattern recognition receptors that have evolved to detect invaders. 
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For instance, host cells possess Toll-like receptor 4 which recognizes bacterial 
lipopolysaccharide (LPS) present on the outer membrane of Gram negative bacteria 
and upregulates immune effector cells (86). Another important aspect of the immune 
system is the complement pathway, which some researchers have hypothesized 
constitutes a link between the innate and adaptive immune system (87). If a pathogen 
enters the blood, it must have some way of escaping the three arms of complement: 
classical, alternative, and lectin pathways as described above (page 5). In addition to 
the previously mentioned examples of complement evasion is the production of a serine 
protease, Pic, by both Shigella flexneri and E. coli O104:H4. This protease cleaves a 
common component of complement and contributes to immune evasion by these two 
pathogens (88). In addition to the complement system, pathogens in the blood must 
also contend with the coagulation system described in the next section. 
Coagulation Pathway 
In the vast majority of people, the blood hemostasis system responds to 
lacerations by forming a clot to stop the bleeding in a process called coagulation. 
Coagulation is tightly controlled to form clots only when needed, thus preventing 
potential damage caused by aberrant clotting, thrombosis, that may lead to stroke or 





Figure 1.2. A simplified coagulation cascade. PT, prothrombin; f, Factor; TF, tissue factor; PK, 
prekallikrein, HK, high-molecular weight kininogen. 
The coagulation cascade was initially described as a waterfall sequence with 
many of the coagulation factors existing as inactive precursor enzymes or zymogens 
(89). Once activated, they go on to cleave the next zymogen, until fibrinogen is cleaved 
and a fibrin clot is formed (Figure 1.2). In addition, regulatory proteins, including 
inhibitors, target many steps of the pathway ensuring that clotting only occurs under the 
correct circumstances. Thrombosis can occur when a repressive protein is down-
regulated or an activator is upregulated, causing intravascular clots to form unchecked. 
The coagulation cascade can be divided into two pathways: the intrinsic pathway and 
the extrinsic pathway. The intrinsic pathway is also known as the contact-dependent 
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pathway while the extrinsic pathway is known as tissue-dependent. The significance of 
the demarcation of these two branches may not be apparent in vivo, but it is useful 
during clinical testing.  
Factor XII (fXII), also known as Hageman factor (90), is the beginning of the 
intrinsic pathway of the coagulation cascade. When fXII comes into contact with a 
negatively-charged surface, it autoactivates into fXIIa and starts the cascade (91). The 
rest of the intrinsic pathway is made up of factor XI (fXI), factor IX (fIX), and factor VIII 
(fVIII). The activated partial thromboplastin time (aPTT) assay is used to measure the 
function of the intrinsic pathway. A negatively charged substance, like kaolin, is added 
to the plasma to activate fXII and clotting time is measured. 
In contrast, the extrinsic pathway starts by the binding of factor VII (fVII) to its 
receptor, tissue factor (TF). The majority of TF is located beneath the endothelial layer 
and, thus, cannot be accessed by fVII without a physical disruption of the endothelium. 
Additionally, high levels of TF can be found in particular organs like the brain, heart, 
lung, uterus, placenta, and testes (92). One possible explanation for this distribution is 
the high amount of damage that could take place if bleeding occurred in any of these 
organs. The prothrombin time (PT) assay, which measures the function of the extrinsic 
pathway, is conducted by adding exogenous TF to the plasma and measuring clot time. 
Both branches eventually meet at factor X (fX) of the common pathway, as components 




Clotting and Pathogenesis 
In addition to preventing loss of blood, clots can also aid the immune system by 
effectively trapping pathogens that enter the bloodstream. Some pathogens can combat 
the effects of coagulation by targeting different effectors in the coagulation cascade. All 
pathogenic group A streptococci encode the protein streptokinase, which activates 
plasminogen (93) (an anti-clotting agent), as do staphylokinase from Staphylococcus 
aureus (94) and Pla protease from Yersina pestis (95). By activating plasminogen, the 
bacteria counteract the formation of localized clots (96) which would otherwise trap the 
bacteria and prevent dissemination.  
Fibrin, the main component of clots, is also necessary for the formation of 
abscesses which can trap bacteria (97). Another bacterium, Aeromonas sobria, 
secretes a serine protease which cleaves fibrinogen (98). As with the plasminogen 
activators, this enzyme decreases clot formation. Neutrophil extracellular traps (NETS) 
could provide a link between bacterial infections and thrombosis (99). When NETS 
entrap a bacterium, they may stimulate clot formation by providing a scaffold for fibrin 
polymerization (99).  
In addition to preventing clots, some bacteria may also evade clots altogether. 
Streptococcus pyogenes expresses a protein (M-protein) that, in addition to preventing 
phagocytosis and protecting from the killing action of complement (100), captures and 
cleaves high molecular weight kininogen (HK), increasing the generation of bradykinin 
(101). By utilizing the vascular permeability inducing properties of bradykinin, S. 
pyogenes may then increase its dissemination throughout the body (101). For bacteria 
17 
 
that enter through the blood stream, having a method to circumvent the action of the 
coagulation system and the impermeability of the blood vessels helps greatly in their 
survival and dissemination. 
Factor XII 
 Lack of a coagulation factor can have dire consequences. While the absence of 
some factors make a fetus unviable, loss of others can lead to a serious bleeding 
disorder, such as hemophilia. FXII-deficiency does not result in a bleeding disorder 
even with an increase in clotting time, as measured by an aPTT assay; however recent 
studies have suggested that loss of fXII may reduce the development of thrombi or clots 
in vivo, leading to reduced rates of heart attacks and strokes. Specifically, mice lacking 
fXII, like humans, have normal bleeding time and display no spontaneous bleeding in 
vivo. However, the fXII-deficient mice are deficient in thrombus formation, thereby 
preventing the generation of life-threatening thrombi in a process that can be reversed 
by adding exogenous human fXII (102). These observations in mice lead to the 
hypothesis that fXII may not be essential for forming clots in response to damaged 
blood vessels but instead be required for forming clots due to intrinsic factors such as 
the presence of a pathogen. 
 The importance of fXII is not limited to the coagulation cascade. In addition to 
activating the intrinsic pathway, fXII also activates C1 esterase, a component of the 
classic complement cascade (not shown), and converts prekallikrein into kallikrein (see 
Figure 1.2). Kallikrein can in turn activate more fXII as well as liberate bradykinin from 
HK as mentioned above (Figure 1.2 and references (103, 104), increasing vascular 
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permeability. Kallikrein can also activate other members of the complement cascade, 
C3 and C5 (105, 106). Given the many different pathways involving fXII, it seems 
unlikely that it is merely a redundant protein and has no in vivo significance, as some 
have suggested.  
Mutations in fXII can lead to dysregulation of bradykinin production. One such 
mutation is the missense mutations T309K (107) and T309R of fXII (108). These familial 
mutations cause hereditary angioedema type III, which involves swelling of 
subcutaneous tissue due to leakage of intravascular fluid. This subgroup of angioedema 
has normal C1-esterase inhibitor suggesting that the mutation in fXII is the cause. The 
T309K and T309R substitutions disrupt O-glycosylation leading to an increase in fXII 
contact activation and generation of bradykinin, followed by the tell-tale sign of 
angioedema, or swelling (109). 
Scope of this Study 
 My work aims to examine the pathogenesis of A. baumannii and determine how 
its T2S system can be instrumental in this process. Chapter two describes the functional 
characterization of the T2S system in A. baumannii and one of its substrates, LipA. We 
use a murine bacteremia model to demonstrate the importance of the T2S system and 
LipA in colonization. In chapter three, we investigate another T2S substrate, CpaA, and 
describe the activity of CpaA against the coagulation factor fXII. This work highlights the 
importance of fXII glycosylation for the cleavage by CpaA. In chapter four, I describe the 
development of a high-throughput screen to identify small molecule inhibitors of the T2S 
system. We optimize a lipase assay as well as develop counterscreens to aid in 
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removing false positives. This screen opens up the possibility of not only identifying 
inhibitors against the T2S system in A. baumannii but also general T2S inhibitors for 
targeting other pathogens. Compounds may be developed into a drug to combat 
antibiotic-resistant pathogens or may be used in the laboratory to study the T2S system 
in multi-drug resistant strains.  
 Altogether, my work provides insight into the pathogenesis of A. baumannii. We 
gain a deeper understanding of how the T2S system may promote bacterial survival in 
the host. To help combat A. baumannii pathogenesis, we have developed a workable 









Chapter II:  
Acinetobacter baumannii is Dependent on the Type II Secretion System and Its 
Substrate LipA for Lipid Utilization and in vivo Fitness 
 
Modified from: 
Johnson TL, Waack U, Smith S, Mobley H, Sandkvist M. 2016. Acinetobacter 
baumannii is dependent on the type II secretion system and its substrate LipA for lipid 
utilization and in vivo fitness. J Bacteriol 198:711–719.  
Abstract  
Gram-negative bacteria express a number of sophisticated secretion systems to 
transport virulence factors across the cell envelope, including the type II secretion (T2S) 
system. Genes for the T2S components GspC through GspN and PilD are conserved 
among isolates of Acinetobacter baumannii, an increasingly common nosocomial 
pathogen that is developing multi-drug resistance at an alarming rate. In contrast to 
most species, however, the T2S genes are dispersed throughout the genome rather 
than linked into one or two operons. Despite this unique genetic organization, we show 
here that the A. baumannii T2S system is functional. Deletion of gspD or gpsE in A. 
baumannii ATCC 17978 results in loss of secretion of LipA, a lipase that catabolizes 
long-chain fatty acids. Due to lack of extracellular lipase, neither the gspD mutant, gspE 
mutant or a lipA deletion strain grows on long-chain fatty acids as a sole 
21 
 
source of carbon, while their growth is indistinguishable from that of the wild-type strain 
in nutrient rich broth. Genetic inactivation of the T2S system and its substrate LipA also 
reduces in vivo fitness in a neutropenic murine model for bacteremia. Both the gspD 
and lipA mutants are outcompeted by the wild-type strain, as judged by their reduced 
numbers in spleen and liver following intravenous co-inoculation. Collectively, our 
findings suggest that the T2S system promotes in vivo survival of A. baumannii by 
transporting a lipase that may contribute to fatty acid metabolism.  
Importance 
Infections by multi-drug resistant Acinetobacter baumannii are a growing health 
concern worldwide, underscoring the need for a better understanding of the molecular 
mechanisms by which this pathogen causes disease. In this study we demonstrate that 
A. baumannii expresses a functional type II secretion (T2S) system that is responsible 
for secretion of LipA, an extracellular lipase required for utilization of exogenously 
added lipids. The T2S system and the secreted lipase support in vivo colonization and 
thus contribute to the pathogenic potential of A. baumannii. 
Introduction 
Acinetobacter baumannii, an increasingly common nosocomial Gram-negative 
pathogen, is responsible for a wide range of infections, including pneumonia, urinary 
tract infections, bacteremia, meningitis, and skin and wound infections (1-3, 9). 
Immunocompromised and severely ill patients in the intensive care unit, individuals with 
extensive wounds or invasive devices, and those undergoing or having recently 
undergone antibiotic regimens are particularly susceptible to A. baumannii infections (4-
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6). Ventilator-associated pneumonia and blood stream infections are the most severe, 
resulting in 25-35% mortality rates (110, 111).  
The pathogenic success of A. baumannii is likely multifactorial, but of importance 
are its ability to persist on dry surfaces, form biofilm, resist complement-mediated killing 
and survive antibiotic treatment (1, 26, 112-114). The escalating frequency of multidrug-
resistant (MDR) strains of A. baumannii is of particular concern. In the past ten years 
there has been an alarming 60% increase in reported MDR clinical isolates 
(http://www.cddep.org). An important and clinically relevant aspect of bacterial infections 
is the ability of bacteria to grow as biofilm (115). These matrix-encased, multi-layer 
bacterial communities are exceptionally resistant to antibiotic treatment and are prone to 
spreading antibiotic resistance through horizontal gene transfer (116, 117) . Clinical 
isolates that form biofilms survive for long periods of time on dry surfaces and are able 
to colonize common hospital equipment, such as ventilator tubes (118). Several factors 
are necessary for abiotic biofilm formation, including a pilus assembly system, the outer 
membrane protein OmpA, and capsular polysaccharide, which is also protective against 
complement-mediated killing (24, 26, 37, 119). 
While research has focused on the mechanisms of antibiotic resistance, biofilm 
formation and the epidemiology of A. baumannii, our understanding of A. baumannii 
pathogenesis is lagging and little is known about the contribution of secreted proteins to 
A. baumannii survival and propagation during infection. Sequencing of several A. 
baumannii genomes revealed that A. baumannii contains genes for a variety of 
transport systems, including the assembly and translocation system for Type IV pilus 
and type IV and type VI secretion systems. The Type IV pilus supports twitching motility 
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of A. baumannii (120), but may also contribute to adhesion, colonization, biofilm 
formation and transformation like type IV pili in other Gram-negative pathogens, while 
the type IV secretion system and type VI secretion system are required for virulence 
and bacterial competition, respectively (121, 122). In addition, A. baumannii possesses 
genes for a type II secretion (T2S) system (47, 123). Bacteria that use the T2S system 
typically reside in the environment; however, they also include pathogens such as Vibrio 
cholerae, Enterotoxigenic Escherichia coli, Pseudomonas aeruginosa, and Legionella 
pneumophila (48, 50, 124, 125). The T2S system mediates the secretion of toxins and 
hydrolytic enzymes, including proteases, lipases, lipoproteins and enzymes that break 
down complex carbohydrates, and is required for in vivo survival and virulence (75, 78, 
79, 85, 126-131). Following inner membrane translocation via the Sec or TAT pathways, 
T2S substrates engage with the T2S system for transport across the outer membrane. 
This multiprotein secretion system is encoded by 12 to 16 general secretion pathway 
(gsp) genes (68, 132, 133). With rare exceptions, mutations in any of the core gsp 
genes, gspC through gspM and pilD, prevent extracellular secretion (133).  
The gsp genes are scattered throughout the A. baumannii genome instead of 
being organized into one or two operons (48). Due to their unusual arrangement, it was 
unclear whether the gsp genes of A. baumannii encode a functional secretion system.  
Here, we demonstrate that the T2S system in A. baumannii is functional and identify a 
lipase as one of its secreted substrates. We show that the extracellular lipase, LipA, as 
well as the T2S system that transports this enzyme across the outer membrane are 
required by A. baumannii to utilize exogenously added lipids and support colonization of  
a mouse in a model of bacteremia.  
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Materials and Methods 
Bacterial Strains and Growth Conditions 
All strains listed in Table 2.1 were cultured in Luria-Bertani (LB) broth or on LB 
agar at 37° C.  Carbenicillin (100 µg/ml) was used for plasmid maintenance.  
Construction of ΔlipA, ΔgspD, ΔgspE1, ΔgspE2, and ΔgspN strains 
Chromosomal DNA isolated from the wild-type (WT) A. baumannii ATCC 17978 
strain was used as the template for polymerase chain reaction (PCR). PCR reactions 
were carried out with Phusion DNA polymerase. Primers were synthesized by IDT 
Technologies.  
To generate the ΔgspD strain, we used the primers indicated in Table 2.2 to 
amplify 500-bp DNA upstream and downstream of the gspD gene as well as the aph-3 
kanamycin cassette and cloned into pCVD442. Transconjugates in which pCVD442 had 
recombined into the A. baumannii genome were selected on LB agar containing 
carbenicillin and chloramphenicol. To select for the second recombination event, 
individual colonies were cultured overnight in LB broth, diluted, cultured to late log 
phase, and spread on LB agar containing 3% sucrose. Sucrose and kanamycin-
resistant, carbenicillin-sensitive isolates were screened for loss of growth on lipid agar. 
Strains that were kanamycin-resistant and carbenicillin-sensitive were designated 
ΔgspD. The deletion was verified by PCR. All other gene deletion strains (ΔlipA, 
ΔgspE1, ΔgspE2, and ΔgspN) were constructed in a similar manner using the 




Construction of plipBA, plipA, pgpsE1, pgspE2, pgspN, and pgspD plasmids 
The lipA and lipB genes were amplified from chromosomal DNA using the 
appropriate primers shown in Table 2.2. The product was ligated into a low-copy, broad-
host vector pMMB67EH to make plipBA. This broad-host expression vector has been 
used in many gram-negative species including P. aeruginosa and V. cholerae (134) and 
is stably maintained in A. baumannii. The construct was verified by sequencing and 
conjugated from the E. coli strain MC1061 into WT and mutant A. baumannii strains. 
The plasmids overexpressing lipA, gspD, gspE1, gspE2, and gspN were constructed 
the same manner.  
Lipid Agar  
Selective agar was utilized to detect extracellular lipase activity. The medium was 
prepared as described previously (135) with modified minimal medium (47.8 mM 
Na2HPO4, 22 mM KH2PO4, 8.5 mM NaCl, 18.7 mM NH4Cl2, 0.1% Tween 20, 0.2 mM 
CaCl2), 40 µg/mL of neutral red and 0.5% filtered-sterilized olive oil. 
Lipase Assay 
The strains were grown in LB broth supplemented with isopropyl-β-D-
thiogalactopyranoside (IPTG) at a 50 µM final concentration to induce the expression of 
plasmid-encoded LipA. Following 16 hr growth, supernatants and cells were separated 
by centrifugation at 3500 rpm for 10 min. A spectrophotometric assay was used to 
measure lipase activity by incubating culture supernatant with 0.9 mM p-nitrophenyl 
myristate in 80 mM Tris-HCl, pH 8.0 and 0.15% Triton X-100 buffer at 37° C and 
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measuring the release of p-nitrophenol at 415 nm over time. All assays were performed 
in triplicate and means and standard deviation are presented. 
SDS-PAGE and Immunoblotting 
Culture supernatants were concentrated by precipitation utilizing pyrogallol red-
molybdate-methanol as described previously (75). The samples were normalized to 
equivalent optical density at 600 nm and subjected to SDS-PAGE and immunoblot 
analysis using antibodies raised against A. calcoaceticus LipA (1:100) (136) and goat 
anti-rabbit IgG-HRP. Immunoblots were imaged using a Typhoon Trio (Amersham 
Biosciences).  
Serine Hydrolase Probe 
Overnight cultures of WT/plipBA and ΔgspD/plipBA were cultured in LB broth 
with 50 µM IPTG at 37°C. Supernatants and cells were separated by centrifugation at 
3500 rpm for 10 min. ActiveXTM FP Serine Hydrolase probe (0.5 µL) (Thermo Scientific) 
was added to 25 µL culture supernatants and incubated at room temperature for 60 min. 
Samples were matched by equivalent OD600, boiled in SDS sample buffer, subjected to 
SDS-PAGE on 4 to 12% Bis-Tris polyacrylamide gels (NuPAGE; Invitrogen), and 
visualized using a Typhoon Trio variable mode imager system and ImageQuant 
software. 
In vitro Competition Assay 
WT and mutant A. baumannii strains were cultured separately overnight in LB 
broth at 37°C. Strains were diluted 1:100 and equivalent numbers of WT and mutant 
strains were pooled and cultured together at 37°C. At 0 (input), 8, and 24 hr, aliquots of 
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the mixed culture were diluted and plated on to LB agar with and without kanamycin. 
CFU counts were determined after 24 hr incubation at 37° C. The competitive index (CI) 
was determined after 24 hours. CI = ([mutant CFU/WT CFU]/[mutant Input CFU/WT 
Input CFU]). 
In vivo competition assay  
Eight-week old female CBA/J mice (Jackson Laboratory) were injected 
intravenously with 150 µL and 100 µL of 20 mg/mL cyclophosphamide four and three 
days, respectively, before the start of the experiment.  Overnight cultures of WT, ΔlipA, 
and ΔgspD A. baumannii strains were diluted in phosphate buffered saline (PBS). 
Inocula of 107 cells of 1:1 ratios of WT:ΔlipA or WT:ΔgspD were administered via tail-
vein injection. After 24 hr, mice were euthanized. Spleens and livers were removed and 
homogenized in PBS and CFU counts were determined after plating on LB with and 
without kanamycin and 24 hr incubation at 37° C. CI was calculated as described 
above. 
Statistical Tests 
A Wilcoxon Signed Ranked test was calculated for the CIs obtained for the in 
vitro and in vivo competition assays. A student t-test was calculated for the lipase 
activity assay. Values were considered significant at P ≤ 0.05. 
Ethics statement 
All mice experiments were performed according to the protocol (PRO00005052) 
approved by the University Committee on Use and Care of Animals at the University of 
28 
 
Michigan. This protocol is in complete compliance with the guidelines for humane use 
and care of laboratory animals mandated by the National Institutes of Health. 
Results 
A. baumannii encodes a functional T2S system. We analyzed the sequenced 
genome of several A. baumannii strains and performed homology searches with the 
T2S genes of V. cholerae and P. aeruginosa. We identified genes for each of the T2S 
components GspC through GspN and PilD (Figure 2.1).  
 
Figure 2.1. T2S genes in A. baumannii.  Putative T2S components are encoded by gspN (A1S_0269), 
gspC (A1S_0270), gspD (A1S_0271), gspE1 (A1S_0616), gspE2 (A1S_2290), gspF (A1S_0369), gspG 
(A1S_0370), gspH (A1S_1562), gspI (A1S_1563), gspJ (A1S_1564), gspK (A1S_1565), gspL 
(A1S_2255), gspM (A1S_2254) and gpsO (also named pilD; A1S_0327). The genes shown in grey were 
deleted using allelic exchange technology. 
In contrast to most species, these genes are scattered around the genome in six 
non-contiguous segments rather than linked into one or two operons, perhaps as a 
result of genome plasticity and the remarkable ability of A. baumannii to acquire foreign 
DNA. To determine whether A. baumannii has a functional T2S system, we utilized A. 
baumannii ATCC 17978, a strain that was originally isolated from a 4 month old with 
fatal meningitis and is amenable to genetic inactivation and plasmid-based 
complementation studies. Using allelic exchange, we inserted a kanamycin resistance 
gene cassette in place of gspD, gspE1, gspE2, or gspN. The gspD gene was chosen 
because in all studied T2S systems, GspD, the outer membrane pore that serves as the 
conduit through which proteins are transported, is absolutely essential for T2S. GspE 




contributes energy for the secretion process by hydrolyzing ATP and is also 
indispensable for secretion. However, as A. baumannii carries two potential gpsE 
genes, gspE1 and gspE2, we deleted each gene to resolve which gspE gene (or both) 
is required for secretion in A. baumannii.   In contrast to GspD and GspE, the role of 
GspN has not yet been determined, and its gene is not present in every species with a 
functional T2S system. As gspN is localized in the same operon as gspD in A. 
baumannii, we wanted to determine whether it is also required for T2S in A. baumannii. 
To complement each deletion strain, we constructed expression vectors encoding the 
wild-type (WT) copy of each mutant gene and expressed them in trans.  
While the ΔgspD and ΔgspE1 mutants grew on LB agar as well as the WT, 
ΔgspE2, and ΔgspN strains, they were unable to grow on minimal agar with olive oil as 
the sole carbon source (Figure 2.2A), a phenotype previously observed for T2S mutants 
of P. aeruginosa and V. cholerae due to their inability to secrete lipase (126, 135). 
Growth was restored when either the ΔgspD or ΔgspE1 mutants were complemented 






Figure 2.2. A. baumannii growth on lipid agar and LB. Growth of strains, from top to bottom,  on lipid 
agar, lipid agar with orlistat, LB agar, and LB agar with orlistat. A. Agar included carbenicillin and IPTG for 
plasmid maintenance and induction of expression of cloned genes. B. Growth of reference strain ATCC 
17978 (WT) and three clinical isolates.  
Sequence analysis of A. baumannii ATCC 17978 identified genes with high 
homology to the genes of the P. aeruginosa and V. cholerae T2S substrate LipA (Figure 
2.3) and its chaperone LipB (76), suggesting that the A. baumannii LipA may also be a 
T2S substrate that is capable of hydrolyzing lipids and generating nutrients for growth. 
To verify that LipA is the secreted substrate responsible for growth of A. baumannii on 
lipid agar, we constructed a lipA deletion strain by replacing the lipA gene with a gene 
encoding kanamycin resistance through homologous recombination. Similarly to the 
ΔgspD and ΔgspE1 mutants, the ΔlipA strain was unable to grow on the minimal lipid 
agar (Figure 2.2A). Growth was restored when the lipA mutant was complemented with 
a plasmid encoding lipA and lipB. We also expressed the plasmid-encoded lipBA genes 
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growth was observed on lipid agar (Figure 2.2A). This suggests that the T2S system is 
active in A. baumannii and is responsible for the extracellular secretion of LipA.   
 
Figure 2.3. Sequence alignment of LipA.  The alignment of LipA from A. baumannii, V. cholerae, and P. 
aeruginosa. Predicted N-terminal signal sequence is underlined. Yellow highlights indicate the catalytic 
residues. 
When A. baumannii is cultured in the absence of lipids in LB broth under 
standard laboratory conditions, the lipBA genes are likely not expressed. This is 
consistent with our inability to detect significant differences in lipase activity between 
culture supernatants of WT, ΔgspD, ΔgspE1, ΔgspE2, ΔgspN, and ΔlipA strains (Figure 
2.4).  Therefore, to quantify the level of LipA secretion, we induced expression of 
plasmid-encoded lipBA genes in the WT, ΔgspD, ΔgspE1, ΔgspE2, and ΔgspN strains. 
This resulted in detectable lipase activity in the culture supernatant of WT/plipBA, 
ΔgspE2/plipBA, and ΔgspN/plipBA using 4-nitrophenyl myristate, while no activity was 
Acinetobacter      MKRNLIFFCAAILSGLSVSATHATNAEQVKSSFVYSTYAQTKYPLVFNHGMAGFNRVGTD 
Pseudomonas        MKKKS-LLPLGLAIGLA-SLAA-------SPLIQASTYTQTKYPIVLAHGMLGFDN---- 
Vibrio             MNKIIILIALSLFSSLIWAGTS-------AHALSQQGYTQTRYPIVLVHGLFGFDT---- 
                   *::   ::  .:  .*  : :           :  . *:**:**:*: **: **:      
 
Acinetobacter      TLGLDYWYQILPDLARNGGNVWATRVSPFNSTEVRGEQLAQQVEEIIAITGKPKVNLIGH 
Pseudomonas        ILGVDYWFGIPSALRRDGAQVYVTEVSQLDTSEVRGEQLLQQVEEIVALSGQPKVNLIGH 
Vibrio             LAGMDYFHGIPQSLTRDGAQVYVAQVSATNSSERRGEQLLAQVESLLAVTGAKKVNLIGH 
                     *:**:. *   * *:*.:*:.:.**  :::* *****  ***.::*::*  ******* 
 
Acinetobacter      SHGGPTIRYVAGIMPEKVASLTTIGAPHKGSPMADVILNVEGTPLSGLA---TLVNWFSA 
Pseudomonas        SHGGPTIRYVAAVRPDLIASATSVGAPHKGSDTADFLRQ-IPPGSAGEAVLSGLVNSLGA 
Vibrio             SHGGPTIRYVASVRPDLVASVTSIGGVHKGSAVADLVRGVIPSGSVSEQVAVGLTQGLVA 
                   ***********.: *: :** *::*. ****  **.:         .      *.: : * 
 
Acinetobacter      AITWAGGLDPNSYPHDSLAGAHSLSTQGSAQFNAQFPMGVPTTSCGEGAYQEKGIYMYSF 
Pseudomonas        LISFLSS--GSTGTQNSLGSLESLNSEGAARFNAKYPQGIPTSACGEGAYKVNGVSYYSW 
Vibrio             LIDLLSG--GKAHPQDPLASLAALTTEGSLKFNQYYPEGVPTSACGEGAYQVNGVRYYSW 
                    *   ..   .:  :: *..  :*.::*: :**  :* *:**::******: :*:  **: 
 
Acinetobacter      SGNKALTNPLDPFDMALTGSSLVVDPFGDNDGLVSRCSAKFGKTIRDDYNWNHLDEVNQV 
Pseudomonas        SGSSPLTNFLDPSDAFLGASSLTFKNGTANDGLVGTCSSHLGMVIRDNYRMNHLDEVNQV 
Vibrio             SGAATVTNILDPSDVAMGLIGLVFN--EPNDGLVATCSTHLGKVIRDDYRMNHLDEINGL 
                   **   :** *** *  :   .*...    *****. **:::* .***:*. *****:* : 
 
Acinetobacter      MGIRSIFAADPVSVYRQHANRLKLQGL 
Pseudomonas        FGLTSLFETSPVSVYRQHANRLKNASL 
Vibrio             LGIHSLFETDPVTLYRQHANRLKQAGL 
                   :*: *:* :.**::*********  .* 
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observed in the ΔgpsD/plipBA and ΔgspE1/plipBA culture supernatants (Figure 2.4A). 
In addition, immunoblotting with antibodies directed against A. calcoaceticus LipA 
detected extracellular LipA when overexpressed in WT A. baumannii but not in the 
ΔgspD mutant, providing further support for the requirement of a functional T2S system 
for extracellular secretion of LipA (Figure 2.4B). 
 
Figure 2.4. Extracellular A. baumannii lipase activity. A. Enzymatic activity of overnight culture 
supernatants against the lipase substrate 4-nitrophenol myristate was measured as a change in 
absorbance at 415 nm per minute and normalized to the absorbance of the culture at 600 nm. Bars show 
standard deviation from the mean (*p≤0.05 and **p≤0.001). B. Concentrated culture supernatants of 
stationary phase WT/plipBA and ΔgspD/plipBA cultures were subjected to SDS-PAGE and immunoblot 
analysis using LipA antibodies. 
Characterization of the secreted substrate, LipA. The A. baumannii T2S substrate, 
LipA, is 54% identical to the well-characterized P. aeruginosa LipA, which is a member 
of the proteobacterial lipase homology group I (137). Lipases within this group require 
helper proteins (chaperones) for their proper folding (138, 139). This relationship 
appears to be true in A. baumannii as well. The ΔlipA/plipA strain, which only 
overexpresses the lipase, exhibited lower extracellular lipase activity than the 




2.4). This difference is likely due to a reduction in secretion of LipA, as proper folding of 
LipA is required for the outer membrane translocation of LipA via the T2S system in 
Pseudomonas glumae (139). Members of the lipase homology group I are serine 
hydrolases with active sites containing the residues Ser-His-Asp/Glu (140, 141). 
Consistent with the overall high sequence homology, sequence alignments indicate that 
the A. baumannii LipA has the catalytic residues Ser-His-Asp (Figure 2.3). To further 
examine the catalytic property of LipA, we used the ActiveX Serine Hydrolase probe, 
which binds covalently to the serine nucleophile in the active site of serine hydrolases. 
As LipA activity is not detected in the supernatant of WT A. baumannii, we incubated 
this probe with supernatants of WT/plipBA and ΔgspD/plipBA cultures induced with 
increasing amounts of IPTG. In the WT/plipBA samples, we observed a band increasing 
in intensity with increasing IPTG induction that corresponded to a protein of ~32 kDa, 
the expected size of LipA (Figure 2.5). In contrast, this band was not present in any of 
the ΔgspD/plipBA samples. Taken together with the sequence homology between LipA 
of A. baumannii and P. aeruginosa, these findings indicate that A. baumannii LipA is a 
secreted serine hydrolase belonging to the lipase homology group I.  
 
Figure 2.5. The ActiveX Serine Protease Probe binds to LipA.  Culture supernatants isolated from 
overnight WT/plipBA and ΔgspD/plipBA cultures induced with increasing concentrations (µM) of IPTG 
were incubated with the ActiveX Serine Protease probe for 1 hr. Samples were subjected to SDS-PAGE 
and Typhoon image analysis as described in the Methods. 
Orlistat is a semisynthetic, therapeutic drug prescribed for the treatment of 
obesity.  It binds to the active site of human pancreatic lipase, thereby preventing the 
32 kDa





enzyme from breaking down dietary lipids in the intestine (142, 143). By incubating 
culture supernatants of WT/plipBA with Orlistat, we learned that it also inhibits A. 
baumannii LipA (Figure 2.4). Through its ability to inhibit LipA, Orlistat was therefore 
capable of inhibiting growth of A. baumannii when added to lipid agar, but not to LB 
agar (Figure 2.2). Similarly, when the recently isolated clinical MDR strains of A. 
baumannii  AYE, 0057, and 5075 were analyzed, they were able to grow on lipid agar in 
the absence, but not in the presence, of Orlistat (Figure 2.2B), suggesting that these 
MDR isolates also secrete lipases that can break down lipids and support fatty acid 
metabolism.  
The T2S system and its secreted substrate, LipA, are required for A. baumannii 
colonization in a murine bacteremia model. We utilized a modified murine 
bacteremia model originally developed for uropathogenic E. coli to determine if the T2S 
system and its substrate, LipA, are required for A. baumannii in vivo fitness (144). Due 
to the low virulence of A. baumannii ATCC 17978 in mice (145), we used an 
experimentally-induced leukopenic mouse model (146) by treating the mice with 
cyclophosphamide prior to infection. To diminish the potential of confounding factors 
between mice, we co-infected each mouse with equal numbers (1 x 107 CFUs/mL) of 
either WT and ΔgspD or WT and ΔlipA strains. After 24 hr, mice were euthanized and 
the spleens and livers were harvested and homogenized. Homogenates were plated on 
LB agar with and without kanamycin, CFUs were determined, and the competitive index 
(CI) was calculated for each mutant strain as described in Material and Methods (Figure 
2.6). A CI value less than 1 indicates a colonization defect of the mutant relative to the 
WT strain. Both mutants were out-competed by the WT strain and exhibited colonization 
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defects in both the spleen and the liver. The ΔgspD strain had a greater disadvantage in 
the spleen than the liver (Spleen: CI=0.024±0.787, p-value < 0.0001; Liver: 
CI=0.163±0.172, p-value < 0.0001) and had a lower CI than the ΔlipA strain in the 
spleen (CI=0.096±0.260, p-value < 0.0001). The reduction in colonization was not 
simply due to the presence of the kanamycin resistance cassette, as a strain with the 
transposon Tn5 containing the kanamycin resistance gene inserted into the ddc gene of 
A. baumannii had no colonization defect in the spleen compared to the WT strain (146). 
In addition, the reduction in colonization of the ΔlipA and ΔgspD mutants is unique to 
the in vivo environment, as in vitro competition experiments in LB broth did not show a 








Figure 2.6. The gspD and lipA genes are required for A. baumannii fitness in a mouse model of 
bacteremia.  Mice were co-inoculated with equal numbers of either WT and ΔgspD or WT and ΔlipA 
strains. Mice were euthanized 24 h post infection, the organs were harvested and the CFUs were 
determined for each strain. The competitive indices were calculated as ([mutant CFU/WT CFU]/[mutant 
Input CFU/WT Input CFU]). For all four competitions, p-values <0.001. 
Discussion 
The T2S system controls the secretion of toxins and hydrolytic enzymes required 
for virulence in a variety of pathogens. Here, we present the first study that identifies a 
functional T2S system in A. baumannii. Not only does A. baumannii possess all the 
genes for a T2S system, but there is a measurable reduction in extracellular LipA 
activity and loss of growth on lipid agar when gspD and gspE1, two of the core T2S 
genes, are deleted. In contrast, deletion of gspE2 has no effect on lipase secretion in A. 
baumannii. While GspE1 supports T2S and the homologous ATPase A1S_0329 likely 
provides energy for type IV pilus assembly, it is not clear what process GspE2 
participates in, if any. Perhaps it affects T2S or type IV pilus biogenesis under very 






































































consistent with its absence in many bacteria with functional T2S systems. In kind, the 
gspN homolog pulN is not required for pullulanase secretion via the T2S system in 
Klebisella oxytoca (147). Similarly to GspE2, GspN may support T2S only under very 
specific growth conditions. Alternatively, it may substitute for GspC to support secretion 
of T2S substrates other than LipA (see below).  
As mentioned earlier, the T2S genes are distributed throughout the genome in 
multiple operons in A. baumannii rather than in one or two operons typical of other 
organisms encoding T2S systems. These smaller operons contain 1-4 gsp genes and, 
in some cases, may represent functional units that encode T2S components that 
directly interact. For example, GspC and GspD interact via the periplasmic domain of 
GspC, and mutations that interfere with their interaction have a negative impact on 
secretion (59, 60). Interestingly, Xanthomonas campestris does not have a gspC gene; 
instead it expresses  GspN, which is required for secretion and interacts with GspD 
(72). Two proteins of the inner membrane platform, GspM and GspL, are encoded on 
another operon, and, in previous studies, we have demonstrated that these proteins 
stabilize each other within the cytoplasmic membrane and can be co-
immunoprecipitated (57). The minor pseudopilins GspI, GspJ and GspK interact and 
may form a subcomplex at the tip of the T2S pseudopilus (148), and they are encoded 
by the same operon that also contains the minor pseudopilin gspH gene. The genes for 
the inner membrane protein GspF and the major pseudopilin GspG are located in their 
own operon. Currently, there is no known interaction between GspF and GspG; 
however, the co-localization of their respective genes suggests a potential functional 
interaction between these proteins in the T2S complex. Finally, while the cytoplasmic 
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ATPase GspE forms a stable complex with GspL at the cytoplasmic membrane (55, 56), 
both gspE1 and gspE2 are encoded on their own individual operons separate from 
gspL. The reason for this is not known, but as discussed above, may suggest that 
GspE1 and GspE2 may be used under different conditions or for the secretion of 
different substrates. The unusual arrangement of the T2S genes presents an interesting 
avenue for further study.  
While the exact role of LipA is currently unknown, it may be required for nutrient 
acquisition by breaking down lipids or long chain fatty acids into shorter forms that are 
imported by the bacterium and used as carbon sources and energy through β-oxidation 
(149). Besides being consumed as nutrients, fatty acids derived through lipid hydrolysis 
may be used as signaling molecules. Specifically, fatty acid signals are capable of 
reverting persistor cells back to a metabolically active state (150). The signaling 
molecule cis-2-dodecenoic acid contributes to virulence in cystic fibrosis Burkholderia 
cenocepacia infections (151), (152).  While lipases may not have been considered as 
virulence factors in the past, the P. aeruginosa lipases LipA and LipC contribute to 
motility, biofilm formation, pyoverdine production, and rhamnolipid production (153-155). 
Other lipases cleave host lipids to generate fatty acids that are integrated into the 
pathogens’ own membranes (156). In addition, the extracellular esterase of Group A 
Streptococcus reduces phagocyte recruitment by hydrolyzing platelet activating factor 
PAF (157), and lipases produced and secreted by the opportunistic fungal pathogen 
Candida albicans support colonization and penetration of host cells (158, 159). 
Determining whether the A. baumannii LipA is involved in nutrient acquisition, signaling, 
or playing another important role in virulence are avenues for future work. 
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The remarkable ability of A. baumannii to develop resistance to multiple 
antibiotics underscores the necessity for novel treatment approaches.  Therapeutics 
that disarm A. baumannii or reduce its in vivo fitness are promising alternatives. One 
possibility is to target LipA with a lipase inhibitor such as Orlistat. Alternatively, 
therapeutic targeting of secretion systems that transport multiple virulence factors to the 
exterior of the bacterium may be of particular interest, as their inactivation should have 
a greater impact than the targeting of individual virulence factors. It is quite possible that 
A. baumannii secretes additional proteins via the T2S besides LipA based on the 
following observations. First, the T2S system is active and supports secretion whether 
exogenous lipids are present or not, while lipA expression appears to require lipids/fatty 
acids (Figures 2.2A and 2.4). Second, the T2S is commonly required for the secretion of 
several proteins in other species. For example, proteomic analyses of culture 
supernatants of L. pneumophila, V. cholerae and Burkholderia pseudomallei indicate 
that greater than 20 different proteins may be dependent on the T2S system for 
extracellular release (75, 85, 160). Future work will focus on identifying additional T2S 








Table 2.1. Plasmids and Bacterial Strains 
Strain or Plasmid Relevant Characteristics Reference 
or Source 
Plasmids   
   pK18mobsacB Suicide vector containing sacB (Km
r) (161) 
   pCVD442 Suicide vector containing sacB (Ap
r) (162) 
   pMMB67EH Low-copy, IPTG-inducible vector (Apr) (163) 
   pgspD pMMB67EH-gspD This Study 
   pgspE1 pMMB67EH-gspE1 This Study 
   pgspE2 pMMB67EH-gspE2 This Study 
   pgspN pMMB67EH-gspN This Study 
   plipA pMMB67EH-lipA This Study 
   plipBA pMMB67EH-lipBA This Study 
E. coli Strains   
   MC1061 F- lac mutant; K-12 laboratory strain (164) 
   MM294/pRK2013 Helper strain for conjugation (165) 
   SY327λpir λpir lysogen; permits replication of 
pCVD442 
(166) 
A. baumannii strains   
   AYE Clinical Strain (167) 
   AB0057 Clinical Strain (168) 
   AB5075 Clinical Strain (169) 
   17978 Wild type for T2S ATCC 
   ΔgspD Replacement of gspD with aph-3 (Kmr) This Study 
   ΔgspE1 Replacement of gspE1 with aph-3 (Kmr) This Study 
   ΔgspE2 Replacement of gspE2 with aph-3 (Kmr) This Study 
   ΔgspN Replacement of gspN with aph-3 (Kmr) This Study 










Table 2.2. Primers used for plasmid construction 
Primer Sequence (5’-3’) Construct(s) 
Generated 










gspD1 GGTTCAACTTCTTACCAATT ΔgspD vector 
gspD2 CCCAGCTGGCAATTCCGGTAAAGCCATAACTCGCGA ΔgspD vector 
gspD3 CTTGACGAGTTCTTCTGAAGCGCCGTAGTAGCATGTTA ΔgspD vector 
gspD4 CGGTGCGGGTTTTGGCACAG ΔgspD vector 
gspD5 CGCGGATCCGTCACCATAAGAGTTAGGAA pgspD 
gspD6 CGCGCATGCCATAACATGCTACTACGGCGCTG pgspD 
gspE1-1 GTTAAACAGACTTCACGCTG ΔgspE1 vector 
gspE1-2 CCCAGCTGGCAATTCCGGGTTTCAGG ΔgspE1 vector 
gspE1-3 CTTGACGAGTTCTTCTGAAAGTGAAG ΔgspE1 vector 
gspE1-4 GGTGCTGTAACTAACCCAG ΔgspE1 vector 
gspE1-5 GACGAGCTCCTCATCATTATAAATTGT pgspE1 
gspE1-6 GACGTCGACGCATTTTTTATATCTTAC pgspE1 
gspE2-1 GAGCCTAGTCTCTTTTTTAA ΔgspE2 vector 
gspE2-2 CTCTTGCGACATGACTTGCTTTTTCTTCATTCAGCC ΔgspE2 vector 
gspE2-3 CTTGACGAGTTCTTCTGACCATTAAATTAAATTTTT ΔgspE2 vector 
gspE2-4 CTACACGTTTTAAAGGCTTATAATC ΔgspE2 vector 
gspE2-5 GACGTCGACATAGATGAGGTGAATCTT pgspE2 
gspE2-6 GACGAATTCATATATTGGGGAAAACAC pgspE2 
gspN1 GTTGAACAGCTTCTAGAATTTGGCG ΔgspN vector 
gspN2 CCCAGCTGGCAATTCCGGCTTTTTCTTCATTCAGCC ΔgspN vector 
gspN3 CTTGACGAGTTCTTCTGAGGTGGTAACTAATGAAAG ΔgspN vector 
gspN4 GCTCTGTAGGTTGAGACGGTGTAGC ΔgspN vector 
gspN5 CACGAATTCCATGTTGGTAAGGCTGAATG pgspN 
gspN6 GCGAAGCTTCCATACTTTCATTAGTT pgspN 
lipA1 AAGCTTGTCGACTTACACACACGTAC ΔlipA vector 
lipA2 GTTGCATGCCGGTTAAAACCCGCCAT ΔlipA vector 
lipA3 TTAGAGCTCCAAGGATTATAAGCTTT ΔlipA vector 
lipA4 TTACCCGGGTTGATATGCGCTTTA ΔlipA vector 
lipA5 GAGGAATTCAGTAAAAAATGAAAAGG plipA 
lipA6 GAGGTCGACTAAAGCGTAAGCTTATA plipA 
lipBA1 CAACGAGCTCAAACTTAAGGAAGATA plipBA 




The Adamalysin-like Protease CpaA Secreted by Acinetobacter baumannii 
Promotes in vivo Colonization and Inactivation of Coagulation Factor XII 
By: Ursula Waack, Mark Warnock, Zachary Huttinger, Andrew Yee, Sara Smith, Ayesh 
Kumar, David Ginsburg, Harry Mobley, Daniel Lawrence, and Maria Sandkvist 
Abstract 
Antibiotic resistant Acinetobacter baumannii is increasingly recognized as a 
cause of difficult-to-treat nosocomial infections. It generally infects immune 
compromised individuals, causing pneumonia, skin and wound infections, urinary tract 
infections, and bacteremia. Previous work has demonstrated that the metalloprotease 
CpaA is secreted by the Type II Secretion System (T2SS) and prolongs clotting time 
when added to human plasma as measured by the Activated Partial Thromboplastin 
Time (aPTT) assay. Here, we show that CpaA interferes with the intrinsic coagulation 
pathway but has no detectable effect on the extrinsic pathway. By utilizing a modified 
aPTT assay, we demonstrate that factor XII (fXII) is the target of CpaA. In addition, we 
map the cleavage site of fXII to the glycosylated proline-rich region of fXII between 
residues Pro308 and the O-linked glycosylated Thr309. While deglycosylation of fXII did 
not affect its activity, it prevented cleavage of fXII by CpaA. Deletion of the cpaA gene 
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resulted in a mutant that is outcompeted by the wild-type A. baumannii strain following 
intravenous co-inoculation of mice. As a determinant of in vivo fitness, CpaA may 
prevent activation of the intrinsic pathway by cleaving fXII, thus allowing A. baumannii to 
escape, without being walled off by clots, and disseminate.  
Importance 
Infections by A. baumannii are becoming more dire due, in part, to the bacteria’s 
high propensity to gain antibiotic resistance. This study aimed to gain further insight into 
how a secreted substrate, CpaA, aids bacterial survival in the bloodstream. We verified 
the necessity of CpaA for the full colonization using a murine bacteremia model. In 
addition, we showed that CpaA cleaves a clotting component, fXII. This cleavage is 
dependent on the presence of glycosylation. This work also provides insight into the 
possible physiological role of fXII in bacterial infections. 
Introduction 
Antibiotic resistance in community and health care settings is increasingly 
common and is especially alarming for gram-negative pathogens as they are rapidly 
becoming resistant to the majority of available drugs (170). Among the more serious 
health care-associated gram-negative infections are those caused by antibiotic resistant 
Acinetobacter baumannii (http://www.cdc.gov/drugresistance). While rarely acquired in 
the community, the recently emerging pathogen A. baumannii survives remarkably well 
in the hospital environment and adapts easily in individuals with compromised immune 
defenses where it is capable of causing pneumonia, skin, wound, and urinary tract 
infections, bacteremia and meningitis (171). The escalating prevalence of life-
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threatening infections caused by multidrug-resistant strains of A. baumannii highlights 
the urgent need for new therapeutic interventions. Analysis of mutants with single gene 
deletions or transposon insertions in different infection models has identified a number 
of A. baumannii factors important for in vivo persistence that may be suitable for 
therapeutic targeting (31, 32, 146, 172-174). For example, survival in the blood stream 
and subsequent colonization by A. baumannii in the spleen and liver is in part supported 
by the type II secretion system (T2SS), a multiprotein complex that transports a variety 
of enzymes, including lipases and proteases, across the Acinetobacter outer membrane 
(174). This was demonstrated using a neutropenic murine model for bacteremia, in 
which the T2SS mutant ∆gspD was outcompeted by the wild type (WT) A. baumannii 
strain. Similar colonization defects were observed with other gspD mutants of A. 
baumannii and the closely related A. nosocomialis in murine pulmonary infection 
models (175, 176). LipA, a lipase that is secreted by the T2SS and required for lipid 
utilization, contributes to the in vivo colonization of A. baumannii (174). However, the 
ΔlipA mutant does not show the same colonization deficiency as the ΔgspD mutant in 
the bacteremic murine model, suggesting that additional proteins delivered by the T2SS 
may have a positive influence on the survival of A. baumannii in the mammalian host.  
Recently, the metalloprotease CpaA was shown to be secreted by the T2SS in A. 
nosocomialis (175). In addition to a functional T2SS, it was demonstrated that CpaA 
folding and/or secretion also requires CpaB, a putative chaperone. CpaA is also 
expressed by several A. baumannii isolates including AB031 and has been suggested 
to interfere with blood coagulation, as cell-free culture supernatant from AB031, but not 
that of a cpaA deletion mutant, increases the clotting time of normal human plasma in 
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an Activated Partial Thromboplastin Time (aPTT) assay (177). The aPTT assay 
primarily measures the activity of the contact activation and common pathways of 
coagulation and is routinely used in combination with the Prothrombin Time (PT) assay 
for the screening of coagulation factor deficiencies.  
The contact activation (or intrinsic) pathway is initiated when circulating 
coagulation factor XII (Hageman factor; fXII) comes in contact with negatively charged 
artificial or biological surfaces such as polyphosphates, nucleic acids, phospholipids, 
misfolded proteins or lipopolysaccharides (LPS) resulting in its autoactivation (178). 
Active fXII (fXIIa), in turn, cleaves and activates Factor XI. In a subsequent cascade of 
proteolytic events, which generates thrombin and induces fibrin polymerization, a clot is 
ultimately formed (Figure 3.1). FXIIa also activates prekallikrein (PK) to generate 
kallikrein, which in reciprocal fashion produces more fXIIa through a feedback loop. In 
addition, kallikrein targets high-molecular-weight kininogen to release bradykinin, a 




Figure 3.1. Schematic of the contact activation (intrinsic) pathway of coagulation. f, factor. 
Here, we show that robust colonization of A. baumannii strain AB031 in a murine 
bacteremia model is supported by the T2SS, in part through the secretion of CpaA to 
the extracellular environment. We also demonstrate that CpaA increases the clotting 
time in the aPTT assay through proteolytic cleavage and inactivation of fXII, both in 
human and murine plasma. Specifically, CpaA targets the glycosylated, proline-rich 
domain of fXII. While deglycosylation of fXII does not interfere with its activity, it 






















Materials and Methods 
Bacterial Strains and Growth Conditions 
Acinetobacter baumannii ATCC 17978, AB031 and their isogenic mutants were 
cultured in Luria-Bertani (LB) broth at 37° C. 100 µg/ml of carbenicillin or 50 µg/ml of 
kanamycin was used for plasmid maintenance.  
Construction of ΔgspD strains 
Chromosomal DNA isolated from the AB031 strain was used as the template for 
PCR. PCR reactions were carried out with Phusion DNA polymerase. Primers were 
synthesized by IDT Technologies.  
To generate the AB031ΔgspD strain, we used a previously made plasmid 
construct pCVDΔgspD(174). This construct was conjugated from the Escherichia coli 
strain SY327λpir into the AB031 A. baumannii strain. Transconjugates in which 
pCVDΔgspD had recombined into the A. baumannii genome were selected on LB agar 
containing carbenicillin. To select for the second recombination event, individual 
colonies were cultured overnight in LB broth, diluted, cultured to late log phase, and 
spread on LB agar containing 3% sucrose. Sucrose and kanamycin resistant and 
carbenicillin sensitive isolates were considered positive for the recombination event. 
Construction of pcpaA and pcpaAB plasmids 
The cpaA and cpaB genes were amplified from chromosomal AB031 DNA using 
primers shown in Table 3.2. The 2,532 bp product was digested with SacI and SphI and 
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ligated into a low-copy, broad-host vector pMMB67EH to make pcpaAB. The construct 
was verified by sequencing and conjugated from the E. coli strain MC1061 into WT and 
ΔgspD A. baumannii 17978 strains to make WTpcpaAB and ΔgspDpcpaAB.  
In vivo competition assay  
Competition assays were carried out as described previously(174). Briefly, 
overnight cultures of AB031 and AB031ΔgspD A. baumannii strains were diluted in 
phosphate buffer saline (PBS). Inocula of 107 cells of equal amounts of AB031 and 
AB031ΔgspD were administered via tail-vein injection into eight-week old female CBA/J 
mice (Jackson Laboratory). Spleens and livers were removed after mice were 
euthanized 24 h post infection. Organs were homogenized in PBS and plated onto LB 
agar with and without kanamycin. CFU counts were determined and used to calculate 
the competitive index (CI). CI = ([mutant CFU/WT CFU]/[mutant Input CFU/WT Input 
CFU]). Competition assays with AB031 and AB031ΔcpaA were carried out in the same 
way. 
Concentration of Supernatant 
Cultures (10 mL) of each A. baumannii strain were grown for 16 hours in LB. The 
supernatant was separated from the cells by centrifugation at 1250 x g for 10 min and 
filter sterilized. The supernatants were concentrated 100X using Amicon Ultra 




Activated partial thromboplastin time (aPTT) assay 
Concentrated cell-free supernatants were mixed with normal human pooled 
plasma (George King) for 20 min at 37° C. An equal volume of aPTT reagent (Pacific 
Hemostasis) was added. After incubation for five minutes, CaCl2 (final 10mM) was 
added. Clot times were determined using an Amelung KC4A Micro Coagulation 
Analyzer. 
To identify the target of CpaA, a modified aPTT assay was performed by first 
incubating concentrated AB031 supernatant with normal plasma. After incubation, the 
plasma was diluted 1:100 and added to human plasma derived from congenital 
coagulation factor deficient donors (George King) and an aPTT assay was performed as 
described above.  
Prothrombin time (PT) assay 
Concentrated cell-free supernatant was incubated with normal human plasma for 
20 min at 37° C. After incubation, PT reagent was added and clot times were 
determined using an Amelung KC4A Micro Coagulation Analyzer. 
SDS-PAGE and Immunoblot Analysis 
Samples were boiled in SDS sample buffer, subjected to SDS-PAGE on 4 to 
12% Bis-Tris polyacrylamide gels (NuPAGE; Invitrogen), and visualized using a 
Typhoon Trio variable mode imager system and ImageQuant software. CpaA was 
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identified by liquid chromatography mass-spectrometry (LC-MS/MS) of gel-excised 
material (MS Bioworks, Ann Arbor, MI).  
Samples were subjected to SDS-PAGE and immunoblotting using 1.25 µg/mL 
mouse anti-fXII biotinalyted antibodies (Molecular Innovations) for fXII, 1:5000 sheep 
anti-fV, and 1:5000 goat anti-fibrinogen. horse radish peroxidase (1:2000 (fXII), 1:10000 
(fV), 1:1000 (fibrinogen, Thermo Scientific) secondary antibodies were used and the blot 
was visualized with SuperSignal West Pico Substrate (Thermo Scientific). Developed 
blots were imaged using a Typhoon Trio. 
N-terminal Sequencing 
Purified fXII was treated with CpaA-containing culture supernatants, subjected to 
SDS-PAGE and transferred to PVDF membrane using 10 mM CAPS, 10% methanol, 
pH 11. The membrane was stained with Coomassie Brilliant Blue R-250, destained, 
washed with water, and then air-dried. The fXII fragments were cut out and subjected to 
automated N-terminal sequencing (Edman degradation) using an ABI 492 protein 
sequencer system (Protein Chemistry Laboratory at Texas A&M University). 
Deglycosylation 
Purified fXII was treated with O-glycosylase (endo-α-N-acetylgalactosaminidase) 
and neuraminidase (acetyl-neuraminyl hydrolase) for 4 hr at 37° C in Glycobuffer 





Ordinary one-way Anovas were performed on the aPPT and modified aPTT 
tests. A Wilcoxon Signed Ranked test was used to analyze the in vivo murine data.  
Ethics Statement 
All mouse experiments were performed according to the protocol 
(PRO00005052) approved by the University Committee on Use and Care of Animals at 
the University of Michigan. This protocol is in complete compliance with the guidelines 
for humane use and care of laboratory animals mandated by the National Institutes of 
Health. 
Results 
We have previously shown that the T2SS supports survival of the A. baumannii 
reference strain ATCC 17978 in a bacteremia model of leukopenic CBA/J mice (174). 
Here, we determined whether the T2SS also promotes the in vivo survival of AB031, an 
A. baumannii strain that was recently isolated from the blood stream of a 55-year-old 
female patient (179). We substituted the gspD gene, which encodes the outer 
membrane pore of the T2SS, with a kanamycin resistance cassette and pooled the 
kanamycin-marked mutant cells and isogenic WT AB031 cells at a ratio of 1:1. The mice 
were inoculated with 107 colony forming units (CFU) of the bacterial pool intravenously 
via the tail vein. Twenty-four hr later, the mice were euthanized, and spleens and livers 
were harvested, homogenized and plated. In contrast to ATCC 17978 (146), AB031 did 
not require immune suppressed mice for infection, and inoculation of 107 bacteria 
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resulted in 105 CFU/liver/mouse 24 h post infection. The CFU of kanamycin sensitive 
(WT AB031) and resistant (ΔgspD mutant) bacteria were counted, and competitive 
indices (CI) were calculated. The mutant was outcompeted by the WT strain in both 
spleen and liver, indicating that the T2SS contributes to in vivo fitness of AB031 as well 
(Figure 3.2). Next we evaluated the role of the T2SS substrate CpaA in in vivo survival 
by analyzing the colonization of a ΔcpaA deletion strain that is deficient in the 
metalloprotease CpaA (177). This protease was recently identified in the T2SS 
proteome of A. nosocomialis (175), and we have confirmed that CpaA is also secreted 
by the T2SS in A. baumannii by SDS-PAGE and mass spectrometry analysis (Figure 
3.3). The ΔcpaA deletion mutant was outcompeted by the WT strain (Figure 3.2), 
suggesting that CpaA is expressed and secreted in vivo and that it supports the survival 
of A. baumannii AB031 in the murine host.  
 
Figure 3.2. The T2SS and CpaA enhance colonization in a murine bacteremia model. Mice were co-
inoculated with equal amounts of either A. baumannii AB031 and AB031 ΔgspD or AB031 and AB031 
ΔcpaA. After 24 h, the spleen and livers were harvested and CFUs determined. The competitive index 
was calculated as follows: [output mutant CFU/output WT CFU]/[input mutant CFU/input WT CFU]. Only 
nine data points are shown for the AB031 ΔgspD/WT AB031 liver samples due to one mouse sample 























Figure 3.3. Secretion of CpaA is dependent on the A. baumannii T2SS.  A. Concentrated culture 
supernatants from AB031 and the T2SS mutant ∆gspD were analyzed by SDS-PAGE and Coomassie 
staining. The AB031 ∆cpaA mutant served as a negative control.  B. CpaA was excised from the gel and 
subjected to LC-MS/MS analysis, which identified 45 exclusive unique peptides, 121 exclusive unique 
spectra and a total of 448 spectra. The resulting sequence coverage (highlighted in yellow) was 84%. No 
peptide representing the signal peptide was identified as the signal peptide is removed during transport of 
CpaA across the cytoplasmic membrane.  
CpaA, a member of the adamalysin-family of secreted metalloproteases, has 
been found to inhibit clotting in human plasma using the aPTT assay(177). We have 
followed up on these findings and confirmed that culture supernatant from the WT 
AB031 strain, but not from the isogenic ΔcpaA mutant, increases the clotting time in an 
aPTT assay in human plasma (Figure 3.4A). In addition, we found that CpaA produced 
by the WT AB031 strain also interferes with clotting of murine plasma (Figure 3.4B). 
Similarly to the ΔcpaA mutant, supernatant from the T2SS mutant ΔgspD had no effect 
on clotting (Figure 3.4). Cloning and over-expression of cpaA and the putative 
chaperone-encoding cpaB also resulted in extracellular release of CpaA in a T2SS 
























cpaA and cpaB genes (Figure 3.5). Not surprisingly, culture supernatant from WT ATCC 
17978 over expressing the protease also extended the clotting time in the aPTT assay, 
while expression of plasmid-encoded cpaA and cpaB in the 17978ΔgspD mutant did not 
diminish the clotting function (Figure 3.6A). The effect on the clotting time in the aPTT 
assay was dose dependent (Figure 3.6B), and the CpaA activity was significantly higher 
in the culture supernatant of ATCC 17978 than in the original AB031 due to 
overexpression, thus generating sufficient amounts of high activity material for 
subsequent analysis. While we confirmed that CpaA does inhibit clotting in the aPTT 
assay, unlike Tilley et al. (177), we found no significant effect of CpaA in a PT assay 
(Figure 3.7A), which measures the activity of the extrinsic pathway (177). Despite not 
having an effect in the PT assay, CpaA does cleave coagulation factor V (fV; Figure 
3.7B), but this cleavage neither inactivates nor activates fV. These findings lead us to 
focus on the intrinsic pathway and the aPTT assay. 
 
Figure 3.4. Clotting time in human and murine plasma is increased when incubated with culture 
supernatant from AB031 but not from strains deficient in either CpaA or the T2SS. A. aPTT after 
incubation of normal human plasma with culture supernatant from AB031, AB031 ΔcpaA or AB031 
ΔgspD. The growth medium LB served as negative control.  ***p ≤ 0.001, by ordinary one-way Anova; 
n=6. B. aPTT after incubation of murine plasma with culture supernatants from the same strains as in A 






















































































































Figure 3.5. Overexpression and secretion of CpaA in the ATCC 17978 strain. Concentrated culture 
supernatants from ATCC17978 or the ∆gspD mutant containing empty vector (p) or a plasmid carrying 
the cpaA and cpaB genes were analyzed by SDS-PAGE and Coomassie staining.  
 
Figure 3.6. Culture supernatant from A. baumannii 17978 overexpressing CpaA and the putative 
chaperone CpaB increases the clotting time in the aPTT assay. A. aPTT assay after incubation of 
normal human plasma with culture supernatant from 17978 or the T2SS mutant 17978∆gspD containing 
either empty vector (p) or pcpaAB. LB medium is included as a negative control. ***p ≤ 0.001, by ordinary 
one-way Anova; n=6. B. Increasing amounts of culture supernatant from 17978/pcpaAB were added to 








































Figure 3.7. CpaA has no effect on clotting in a PT assay. A. Increasing amounts of supernatant from 
ATCC 17978/pcpaAB containing CpaA was added to normal human plasma (NHP) and analyzed for 
clotting using a PT assay; n=6, ***p<0.001. The snake venom protease RVV-V, a factor V activator, and 
the buffer TBS were included as controls.  B. Human plasma was incubated with or without CpaA and 
subjected to SDS-PAGE and immunoblotting using α-fV antibody. fV deficient plasma incubated in the 
absence of CpaA was used as a negative control. C. Human plasma was incubated with or without CpaA, 
subjected to SDS-PAGE, and immunoblotted using α-fibrinogen antibody. Purified fibrinogen was used as 
control.  
Since the aPTT assay primarily measures the intrinsic coagulation pathway, to 
identify the target of CpaA we used a modified aPTT factor assay with a variety of 
factor-deficient human plasmas. Normal plasma was first incubated with CpaA from 
culture supernatant of ATCC 17978/pcpaAB or LB media as control. The samples were 
then diluted 1:100 into various human plasmas lacking specific factors of the intrinsic 
pathway, and an aPTT assay performed. In this way, the factor inactivated by CpaA in 
the normal plasma will be unable to complement the specific factor deficient plasma. 
The finding that the clotting time was increased only when CpaA treated normal plasma 
was added to fXII deficient plasma suggested that fXII is inactivated by CpaA (Figure 
3.8A). This result was confirmed by immunoblotting (Figue 3.8B), which showed that 
CpaA efficiently cleaves both purified fXII and fXII in human plasma. A similar factor 
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the factor XII deficient human plasma, confirming that fXII is the target of CpaA in both 
human and mouse plasma (Figure 3.8C).  
 
Figure 3.8. CpaA cleaves fXII. A. Normal human plasma was incubated with (+ CpaA) or without ( - 
CpaA) culture supernatant from 17978/pcpaAB, diluted 1:100 and added to different factor deficient 
plasma as indicated. Clotting time was determined using an aPTT assay. ***p ≤ 0.0001, by ordinary one-
way anova; n=6. B. Normal human plasma (NHP) was incubated with (+) or without (-) CpaA present in 
culture supernatant from 17978/pcpaAB for 20 min. fXII deficient control incubated without CpaA was 
used as a control. fXII was detected using α-fXII antibody. C. Murine plasma incubated with or without 
CpaA, diluted 1:100, added to fXII deficient plasma and tested in an aPTT assay. ***p ≤ 0.001, by 
ordinary one-way Anova; n=6.       
SDS-PAGE and coomassie staining indicated that treatment of purified human 
fXII with CpaA resulted in 3 distinct bands (Figure 3.9A; lane 3). The bands were 
excised from the gel, and the cleavage site(s) was identified by N-terminal protein 
sequencing via Edman degradation. The single low molecular weight band (filled arrow) 
represents the N-terminal fXII fragment (not shown). The two slower migrating 
fragments (lane 3; open arrows) possessed identical N-termini, XXRTPPQSQX, 
indicating that they are the same species with possible differences in glycosylation or C-
terminal heterogeneity (Figure 3.9B). The first two residues and the last marked as X 
could not be identified by N-terminal sequencing as they are O-linked glycosylated 
threonines [SwissProt entry P00748 and (180)]. However, as residues 3 through 9 were 
identified for both fragments, the results suggest that the sequence represents residues 








































Thr309. Interestingly, Thr309 is modified with an O-linked mucin-type 
HexHexNAcNeuNAc glycan (109), suggesting that CpaA may be specific for O-linked 
glycosylated residues. To determine whether glycosylation is required for CpaA 
cleavage, we treated fXII with O-glycosidase and neuraminidase to deglycosylate fXII 
before incubating it with CpaA. SDS-PAGE analysis indicated that deglycosylation 
resulted in increased mobility of fXII (Figure 3.9A; lane 4), but more importantly, 
prevented cleavage by CpaA (Figure 3.9A; lane 5). The effect of deglycosylated fXII 
with and without treatment with CpaA was also analyzed in a modified aPTT assay in 
which we determined the ability of purified fXII to restore normal clotting to fXII deficient 
plasma. The results in Figure 3.9C show that deglycosylated fXII fully restored clotting 
when added to fXII deficient plasma, whether it had been incubated with CpaA or not, 
providing further support that deglycosylated fXII is resistant to CpaA. 
It is possible that fXII is not the only physiological target of CpaA. Even though 
we did not observe an effect in clot formation, fV is also cleaved by CpaA (Figure 3.7). It 
is possible that cleavage of fV does not interfere with activation of fV into fVa. Perhaps 
there is a common O-linked glycosylation recognition site in fXII and fV, but only 
cleavage of fXII leads to inactivation. Tilley et al. also suggested that fibrinogen may be 
a target of CpaA as well(177), but we were unable to detect cleavage of fibrinogen in 






Figure 3.9. Glycosylation is necessary for cleavage of fXII by CpaA. A. Purified fXII was incubated 
without and with neuraminidase and O-glycosidase and then subjected to culture supernatant containing 
CpaA followed by SDS-PAGE and comassie staining. Neuraminidase (NA) and O-glycosidase (O-gly) are 
shown as controls. The positions of CpaA (arrow head) and cleaved fXII fragments (open and filled 
arrows) are indicated on the right. B. Alignment of N-terminal sequencing result of the fXII fragments 
(indicated by open arrows in A) with amino acid sequence of human fXII. Residues for positions 1,2 and 
10 could not be identified and are marked with X. C. Purified fXII or deglycosylated fXII was added to fXII 
deficient plasma following incubation with and without CpaA and tested for clotting in the aPTT assay. 
Results with normal human plasma (NHP) are shown for comparison. ***p ≤ 0.001, by ordinary one-way 
Anova; n=6. 
Discussion 
Our studies have focused on the putative function of the metalloprotease, CpaA, 
which is secreted by the T2SS in A. baumannii. Both the T2SS and CpaA were shown 
to be required for efficient colonization of A. baumannii in a conventional murine 
bacteremia model. In addition, the clotting factor fXII was recognized as the substrate 
for CpaA in both human and murine plasma. N-terminal sequencing of fXII fragments, 
generated following treatment with CpaA, identified the cleavage site between Pro308 
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Glycosylation of T309 may contribute to specificity of CpaA, as deglycosylation of fXII 
prevents cleavage while it does not affect fXII’s clotting activity per se.  
While our previous work demonstrated the advantage of possessing the T2S 
system for colonization of ATCC 17978 (174), this is also true for the AB031 strain. 
However, a neutropenic state was not required to observe a detectable bacterial burden 
in the liver and spleen for AB031, suggesting that AB031 is better able to resist host 
defense mechanisms. The necessity of the T2S system in multiple strains of A. 
baumannii is indicative of a wide-spread role of the system and its substrates in the 
species as a whole. While the defect in colonization was equivalent for the spleen and 
the liver for the T2S mutant, there was a difference between the organs for the ΔcpaA 
mutant with the liver showing a greater difference than the spleen. While this requires 
further investigation, the liver is the site of  fXII synthesis (181), and it is possible that A. 
baumannii is exposed to higher levels of fXII in this organ thus decreasing the 
competitiveness of the ΔcpaA mutant.  
The original study that discovered fXII noted that Mr. Hageman, the individual 
who lacked fXII, exhibited no blood or clotting disorder(90). However, recent studies 
have demonstrated that fXII promotes intravascular thrombus formation (102, 182, 183). 
CpaA may cleave fXII to prevent the formation of clots. Without the hindrance of a clot, 
A. baumannii would be more likely to escape and gain access to other organs. Another 
example of a bacterium that is hypothesized to escape clot-mediated trapping is group 
A streptococcus (GAS). GAS produces streptokinase, which can dissolve a clot trapping 
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the bacterium by activating plasminogen(93). Thus, GAS destroys the clot whereas A. 
baumannii may prevent the formation of a clot. 
It is possible that targeting fXII to prevent clot formation might not be the 
mechanism by which CpaA supports colonization. Instead or in addition, CpaA may 
prevent activation of the kallikrein/kinin pathway. As mentioned previously, fXIIa 
mediated activation of prekallikrein releases kallikrein, which, in turn, liberates 
bradykinin from high molecular weight kininogen (Figure 3.1). Bradykinin is a peptide 
hormone with a wide array of roles. Bradykinin can allow for the efflux of immune cells 
by increasing vascular permeability and vasodilation by binding to B-2 receptors(184). 
Bradykinin can be metabolized and, once metabolized, binds B-1 receptors(184). 
Binding of both the B-2 and B-1 receptor lead to release of immune and inflammation 
mediators that are immune cell dependent(185). By inactivating fXII and thus reducing 
the generation of bradykinin, CpaA could, in part, prevent the recruitment of immune 
mediators, including neutrophils and thus support survival of A. baumannii.  
Interestingly, several mutations in the region of the CpaA cleavage site in fXII 
have been identified in patients with hereditary angioedema type III including two 
missense mutations at Thr309(107, 108). Inheritance of either Lys or Arg substitution at 
Thr309 (thus removing the O-linked glycosylation site) is associated with an autosomal 
dominant form of this disorder in multiple families. Intriguingly, these substitutions were 
recently shown to lead to increased contact mediated autoactivation of fXII (109). Taken 
together with our data, these findings raise the possibility that resistance of these 
mutant forms of fXII to inactivation by CpaA or other related microbial protease(s) could 
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provide a selective advantage to infection by A. baumannii balancing the manifestations 
of angioedema. 
 
Table 3.1. Strains and plasmids used in this study. 
Strain or Plasmid Relevant Characteristics Reference or 
Source 
Plasmids   
   pK18mobsacB Suicide vector containing sacB (Km
r) (161) 
   pCVD442 Suicide vector containing sacB (Ap
r) (162) 
   pMMB67EH Low-copy, IPTG-inducible vector (Apr) (163) 
   pgspD pMMB67EH-gspD (174) 
   pcpaA pMMB67EH-cpaA This study 
   pcpaAB pMMB67EH-cpaAB This study 
   pcpaA-kan pMMB960-cpaA This study 
   pcpaAB-kan pMMB960-cpaAB This study 
E. coli Strains   
   MC1061 F
- lac mutant; K-12 laboratory strain (164) 
   MM294/pRK2013 Helper strain for conjugation (165) 
   SY327λpir λpir lysogen; permits replication of 
pCVD442 
(166) 
A. baumannii strains   
   AB031 Clinical Strain (177) 
   AB031ΔcpaA Replacement of cpaA with aacC1 
(Gmr) 
(177) 
   AB031ΔgspD Replacement of gspD with aph-3 
(Kmr) 
This study 
   17978 Wild type for T2S ATCC 
   17978ΔgspD Replacement of gspD with aph-3 
(Kmr) 
(174) 
Table 3.2. Primers used for plasmid construction. 
Primer Sequence (5’-3’) Construct(s) Generated 
CpaA For GAGGAGCTCTGGTTTGCTAACCTGC pcpaA, pcpaAB 
CpaA Rev GAGGCATGC CCTATTAACAATTTAT pcpaA 





Chapter IV:  
Targeting the Type II Secretion System: The Development, Optimization, and 
Validation of a High-Throughput Screen to Identify Small Molecule Inhibitors 
By: Ursula Waack, Tanya L. Johnson, Khalil Chedid, Chuanwu Xi, Lyle A. Simmons, 
Harry L.T. Mobley, and Maria Sandkvist  
Abstract 
Multi- and pan-drug resistant bacterial strains, especially nosocomial pathogens, 
present an increasing problem for healthcare facilities. Due to its rapid rise in antibiotic 
resistance, Acinetobacter baumannii is one of the most concerning Gram-negative 
species.  A. baumannii typically infects immune compromised individuals resulting in a 
variety of outcomes, including pneumonia and bacteremia. Using a murine model for 
bacteremia, we have previously shown that the type II secretion system (T2SS) 
contributes to in vivo fitness of A. baumannii. Here, we provide support for a role of the 
T2SS in protecting A. baumannii from human complement as deletion of the T2SS 
gene, gspD, resulted in a 100-fold reduction in surviving cells when incubated with 
human serum. This effect was abrogated in the presence of serum deficient in Factor B, 
a component of the alternative pathway of complement activation, indicating that the 
T2SS protects A. baumannii against the alternative complement pathway. Because 
inactivation of the T2SS results in loss of secretion of multiple enzymes, reduced in vivo 
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fitness, and increased sensitivity to human complement, the T2SS may be a suitable 
target for therapeutic intervention. Accordingly, we developed and optimized a high-
throughput screening (HTS) assay based on extracellular lipase activity to identify small 
molecule inhibitors of the T2SS. We tested the reproducibility of our assay using a 
6400-compound library. With small variation within controls and a dynamic range 
between positive and negative controls, our assay had a z-factor of 0.65, establishing its 
suitability for HTS. Our screen identified every lipase inhibitor in the library 
demonstrating the specificity of the assay. To screen out false positives, we also 
developed and optimized two counter assays to eliminate inhibitors of lipase activity and 
lipase expression. By implementing the counter assays, we found that all seven tricyclic 
antidepressants present in the library are inhibitors of the lipase, highlighting the 
potential of identifying alternative targets for approved pharmaceuticals. Taken together, 
our proof-of-concept pilot study indicates that the HTS regimen is simple, reproducible, 
robust, and specific and that it can be used to screen larger libraries for the identification 
of T2SS inhibitors that may be developed into novel A. baumannii therapeutics. 
Introduction 
A growing concern in hospitals, nursing homes and other healthcare facilities is 
the increasing frequency of antibiotic resistant infections that result in longer hospital 
stays, higher costs and increased mortality. The ESKAPE pathogens Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter species have attracted considerable 
attention as they cause the majority of nosocomial infections  (11). Infections caused by 
A. baumannii are prevalent with approximately 45,000 cases per year in the United 
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States alone. Globally, there are about 1 million cases annually (186), and reports 
suggest that A. baumannii may be the leading cause of nosocomial infections in some 
countries (187). Some 50% of these infections are caused by antibiotic-resistant strains 
(186). Exposure to A. baumannii can result in a variety of infections including 
pneumonia, urinary tract infection, bacteremia, meningitis, skin and wound infections 
that may lead to sepsis (6, 9). Considered an opportunist, A. baumannii typically infects 
immune-compromised individuals, but more recently isolated strains may not be 
restricted to this patient population, possibly as a consequence of increased virulence 
(169). The remarkable ability of A. baumannii to form biofilm and resist dry 
environments (112, 118) may explain its prevalence in healthcare environments (10, 
114). Additional contributing factors include multi- or pan-antibiotic resistance (6, 13), 
which is due, in part, to intrinsic properties of the outer membrane of A. baumannii and 
its notable ability to acquire foreign DNA through horizontal gene transfer (12).  
The rise in antibiotic resistance rapidly reduces the options of effective treatment 
and calls for the identification of new therapeutic approaches. A recommended strategy 
combines antibiotics with drugs that target resistance mechanisms such as Augmentin, 
which consists of Amoxicillin and the β-lactamase inhibitor Clavulanate. Other feasible 
options include the combination of antibiotics with inhibitors of drug efflux pumps or 
outer membrane permeabilizers (188). Identification of new therapeutic targets is also 
necessary. Candidates may include essential processes such as lipopolysaccharide 
synthesis and transport as well as factors that contribute to in vivo fitness and virulence.  
One of the first studies to target virulence factors using HTS of small molecule 
libraries identified a compound that inhibits dimerization of ToxT, a virulence regulator in 
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Vibrio cholerae (189, 190). This inhibitor abolishes the production of cholera toxin and 
decreases TCP-mediated colonization in an infant mouse model (189).  Other studies 
have screened for biologicals or chemical compounds that target colonization factors 
such as curli and type 1 pili, toxins, protein secretion pathways or quorum sensing 
systems (188, 191-193). With a few exceptions, it is too soon to evaluate the outcome 
of these studies and their success; however, some of these potential anti-virulence 
drugs are in various stages of development and are being analyzed in animal models or 
clinical trials (193-195). An IgG antibody that targets the binding of anthrax toxin to its 
receptor is currently used as an antitoxin in combination therapy for the treatment of 
Bacillus anthracis infections (196) and demonstrates the feasibility of targeting disease-
causing components of pathogens.  
Secretion systems are particularly attractive targets for alternative therapeutics, 
as their inactivation interferes with the delivery of entire batteries of secreted virulence 
factors. Therefore, several HTSs have been designed to identify small molecule 
inhibitors of the type III secretion system, which is present in many Gram-negative 
human pathogens and secretes a wide variety of virulence effectors (197, 198). Another 
secretion system, the type II secretion system (T2SS), is responsible for the secretion of 
numerous degradative enzymes and toxins that contribute to survival in the environment 
and the mammalian host and may also be a suitable target for alternative therapeutics 
(48, 50, 199). As with many gram-negative pathogens, A. baumannii possesses a 
functional T2SS (174, 176). The T2SS forms an apparatus that spans both the inner 
and outer membrane and is encoded by 12 essential genes, gspC-M and pilD (68, 132). 
T2S substrates are synthesized with an N-terminal signal peptide that directs 
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translocation from the cytoplasm to the periplasm via the general export (Sec) or twin 
arginine translocation (Tat) pathways. Once in the periplasm, the signal sequence is 
cleaved, the protein folds, and then interacts with the T2SS to finally exit the cell via  a 
gated outer membrane pore formed by GspD  (64, 200). GspD connects to GspC, one 
of the components of the inner membrane platform that also consists of the 
transmembrane proteins GpsF, L, and M (53, 57, 59, 201). The pseudopilins GspG, H, 
I, J, and K make a pseudopilus, a structure homologous to the Type IV pilus, whereas 
PilD cleaves and methylates the pseudopilin subunits prior to their assembly (65-67). 
The entire system is powered by a cytoplasmic ATPase, GspE (54, 202). All of these 
proteins, including their expression and interactions, are potential targets for a 
therapeutic compound (Figure 4.1). 
Recent work by our laboratory and others has demonstrated that a functional 
T2SS aids in A. baumannii and A. nosocomialis colonization (174-176). Inactivation of 
the T2SS or one of its substrates diminishes survival in murine models for bacteremia 
and pneumonia, indicating that screening for compounds that target the T2SS may 
identify A. baumannii virulence inhibitors. In this study, we describe the development 
and optimization of a high-throughput screen to identify small molecule inhibitors of the 
T2SS in A. baumannii. In addition, we highlight the need for inclusion of high-throughput 





Figure 4.1. Potential Targets of a T2SS Inhibitor. A T2S inhibitor may block transcription of the T2S 
genes or translation, post-translational modification, protein-protein interactions or function of the T2S 
proteins. Blocking the recognition of the proteins to be secreted by the T2S system could also halt 
secretion. 
Methods 
Bacterial Strains and Plasmids 
 All bacterial strains and plasmids are described in Table 4.3. All strains were 
cultured overnight in Luria-Bertani (LB) broth. When necessary, LB broth was 
supplemented with carbenicillin (100 µg/ml) to maintain the plasmid. 
Compound Library 
 All compounds tested in this study are from commercially available libraries 

























mM by the Center for Chemical Genomics at the University of Michigan.  The five 
libraries include MS2400, NCC, Pathways, Prestwick, and LOPAC. MS2400 is a 
collection of FDA approved drugs plus compounds with known biological activity 
obtained from Microscource Discovery (Spectrum Collection). NCC is a library with 
compounds that have been used in human clinical trials. The Pathways collection is 
comprised of known active compounds with a variety of targets. The Prestwick library is 
composed of approved drugs which are safe for use in humans. Finally, the LOPAC 
collection is the Library of Pharmacologically Active Compounds from Sigma.  
Serum bactericidal assay 
 After cultures were grown overnight in LB, the cells were separated from 
supernatant by centrifugation for 10 min at 3,500 rpm. The cells were washed in PBS 
and diluted 1:100. Equal volumes of cells and either 100% normal human serum, heat-
inactivated human serum or factor depleted sera were incubated together for 30 min at 
37° C. Samples were diluted and plated on LB agar to obtain CFUs. 
High-Throughput Lipase Assay 
Overnight cultures of wild-type (WT) A. baumannii 17978/plipBA and 
17978ΔgspD/plipBA were grown in LB broth. After growth, the cultures were centrifuged 
for 10 min at 3500 rpm to separate cells and supernatant. The supernatant was 
removed and the pellet was washed in Mueller-Hinton 2 (MH) and resuspended in the 
original volume. 10 µL of MH was added to each well of a 384-well Greiner 784080 
plate. Compounds in DMSO or the DMSO control were added to the wells (0.05 µL) 
using Perkin Elmer Sciclone liquid handler with a 50 nl pintool attachment (in primary 
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assay). For concentration-response assays, the TTP LabTech Mosquito X1 was used to 
place variable volumes (0.02 – 1.2 µL) of compounds to the wells. 17978/plipBA was 
diluted and added to all the negative control wells as well as to the sample wells while 
17978ΔgspD/plipBA was diluted and added to the positive control wells. All cultures had 
a starting OD600 of 0.005 and were supplemented with 50 µM IPTG (isopropyl-β-D-
thiogalactopyranoside) to induce expression of the lipBA genes. Plates were centrifuged 
1 min at 1,000 rpm to ensure all liquid was at the bottom of the well. Plates were 
incubated overnight at 24°C in a humidified incubator. After 16 hour incubation, the 
OD600 value of each culture was recorded. An optimized lipase assay was used to 
measure lipase activity. Briefly, the cultures were incubated with 0.45 mM p-nitrophenyl 
myristate, 80 mM Tris-HCl (pH 8.0), and 0.15% Triton X-100 and the absorbance at 415 
nm was measured over time using the PE EnVision Multimode Plate Reader. All data 
were uploaded to MScreen for analysis. MScreen is a data analysis and storage system 
created by the Center for Chemical Genomics intended for the processing of high-
throughput data generated by users of the center(203).  
Lipase Inhibitor Assay 
Cultures of A. baumannii 17978/plipBA and 17978ΔgspD/plipBA were grown 
overnight in LB broth with 50 µM IPTG and the supernatant and cells were separated by 
centrifugation. For concentration-response assays, the TTP LabTech Mosquito X1 was 
used to add variable volumes (0.02 – 1.2 µl) of compounds. Supernatant was added to 
the wells, buffer with lipase substrate was added and the change in OD415 was recorded 
as above. All data were uploaded to MScreen for analysis. 
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GFP Expression Assay 
A. baumannii 17978/p and 17978/pgfp cultures were grown O/N as above. Cells 
were washed as described above for the lipase assay. Compounds in DMSO or the 
DMSO control were added to the wells of a black low-volume Greiner 784073 plate 
using Perkin Elmer Sciclone liquid handler with a 50 nl pintool attachment calibrated to 
deliver 200nM.  For concentration-response assays, the TTP LabTech Mosquito X1 was 
used to place variable volumes (0.02 – 1.2 ul).  Cultures were diluted to OD600=0.005 in 
LB supplemented with 75 µM IPTG. Plates were centrifuged for 1 min at 1,000 rpm to 
ensure all liquid was at the bottom of the well and incubated overnight at room 
temperature in a humidified incubator. Fluorescence was measured after growth using a 
BMGLabtech PHERAstar (485 nm excitation, 520 nm emission). All data were uploaded 
to MScreen. 
Lipase Assay  
A modified version of the lipase assay reported by Johnson et al. was used(174). 
Briefly, overnight cultures of A. baumannii strains were cultured in LB broth. The lipase 
activity of each culture was measured by a spectrophotometer after addition of 0.9 mM 
of the substrate, 4-nitrophenyl myristate in 80 mM Tris/0.15% Triton X-100 buffer. The 
absorbance at 415 nm was measured over time at 37°C. All assays were performed in 
triplicate with means and standard deviations presented. 
Results 
Recent studies have demonstrated the significance of the T2SS in colonization 
by A. baumannii and A. nosocomialis in murine models of bacteremia and pneumonia 
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(174-176). In our study,  we also revealed that one of the secreted proteins, LipA, 
contributes to colonization (174), possibly by aiding in nutrient acquisition through lipid 
hydrolysis. It is quite likely that other T2S substrates including the lipase LipH, the 
phospholipase LipAN, and/or other putative enzymes and proteases identified by 
proteomics similarly contribute to in vivo survival of A. baumannii (175, 176).  
In addition, a “serum resistance factor” may be secreted by the T2SS, as a 
previous study aimed at identifying factors that contribute to A. baumannii proliferation 
in human serum identified a gspN transposon insertion mutant with diminished serum 
survival (31). Here, we followed up on this finding by testing the possibility that an intact 
T2SS is required for A. baumannii ATCC 17978 to resist serum complement. Many 
isolates of A. baumannii survive in the presence of 100% serum; however, ATCC 17978 
is sensitive to this concentration; therefore, we conducted our experiments using 50% 
serum. The WT and ΔgspD mutant strains were incubated in 50% pooled human sera, 
and the CFUs were determined after 30 min incubation at 37°C. As a control, we used 
the ΔlipA mutant that has an intact T2SS but lacks one of the T2S substrates, LipA. We 
also treated the WT and mutant strains with heat-inactivated (HI; 56°C, 30 min) serum, 
in which the complement system is inactivated. While no loss of viability was observed 
for the WT and ΔlipA strains, only 1% of the ΔgspD mutant cells survived 30 min in 
normal serum (Figure 4.2A). Next, we subjected the ΔgspD mutant cells to factor C1q-
depleted and factor B-depleted human sera. The majority of ΔgspD mutant cells 
survived in the absence of factor B, which is required for activation of the alternative 
complement pathway; however, in the C1q-depleted serum, which is deficient in the 
classical pathway yet contains factor B, less than 0.05% of the ΔgspD mutant cells were 
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viable (Figure 4.2B). This result suggests that the T2SS directs the outer membrane 
translocation of a factor that provides protection from the alternative pathway. In 
contrast, the ΔgspN mutant was not affected by human serum (Figure 4.2A), a result 
that differs from the study published by Jacobs et al. (31). The lack of a serum sensitive 
phenotype for the ΔgspN mutant is consistent with our earlier finding that GspN is not 
required for T2S in A. baumannii (174) and with the discovery by Wang et al. that 
showed GspN is not needed for survival of A. baumannii in a mouse model of 
pneumonia (172). We suggest, therefore, that the diminished growth observed for the 
gspN transposon mutant in human serum is due to a polar effect of the transposon on 
the downstream gene, gspD, which we show here is required for full protection from 
serum complement. Taken together with earlier findings, these results support the 
model that extracellular proteins secreted by the T2SS play important roles in the 






Figure 4.2. Survival in serum depends on the T2SS. A. Cells from overnight cultures were washed and 
incubated for 30 min at 37° C with either 50% normal human serum or heat-inactivated serum. Cells were 
plated for CFUs following incubation. * p<0.05 by Student t-test; n=3. B. Cells from overnight cultures 
were washed and incubated as above with normal human serum, Factor B deficient, C1q deficient, or 
heat-inactivated serum.  n=3, *** p<0.001 by Student t-test. 
Inhibiting the function of the T2SS would simultaneously prevent the secretion of 
many substrates, causing a greater impact on A. baumannii survival than targeting 
individual T2S substrates. The T2SS components and their interactions (Figure 4.1) 
provide ideal targets for therapeutics because they are unique to the T2SS and are 
absent from most members of the human microbiota. Compounds could block the 
function of the outer membrane pore, inhibit interactions between the different 
components of the secretion apparatus, prevent recognition of the substrates by the 
apparatus, or interfere with the expression of the T2S proteins (Figure 4.1). To identify 





Development of High Throughput Assay 
In our previous study, we used a colorimetric lipase assay to measure the activity 
of the T2S lipase LipA in culture supernatant of strains overexpressing plasmid encoded 
lipBA genes. We used an overexpression strain because endogenous lipase production 
is very low during growth of A. baumannii ATCC 17978 in LB, presenting a challenge for 
detection (174). Further, because lipase activity is undetectable in the culture 
supernatant of T2SS mutants, this provides a robust assay that can be used as a 
readout for T2SS activity (174) for the purpose of identifying T2SS inhibitors. However, 
testing the effect of a large number of compounds on LipA activity in cell-free culture 
supernatants would be cumbersome, as it would involve an extra processing step. 
Thus, we compared cell-free culture supernatants and unfractionated cultures for T2SS 






Figure 4.3. Detection of T2S lipase activity in either supernatants separated from cells or 
unfractionated bacterial cultures. Enzymatic activity of either the supernatant, cells, or unfractionated 
cultures of 17978/plipBA or 17978ΔgspD/plipBA strains grown overnight in 5 mL LB broth. The substrate 
4-nitrophenyl-myristate was added to the samples and the change in OD
415
 was recorded over time. 
Values were normalized to the OD
600
 of the original cultures. *** p < 0.001 by Two Way Anova. 
The culture supernatant and unfractionated culture of the 17978/plipBA strain 
both contained significant lipase activity toward 4-nitrophenyl myristate, while there was 
little to no activity either in the supernatant or culture of the T2SS mutant, 
17978ΔgspD/plipBA. More importantly, the vast majority of the lipase activity in the 
unfractionated culture was generated by extracellular LipA, thus allowing us to omit the 
step in which the culture supernatant is separated from cells. Consequently, we 
developed an assay for HTS of small molecule inhibitors of T2SS in which the lipase 
substrate was added directly to the bacterial cultures following growth in the presence 
and absence of compounds.  
In our first attempt to miniaturize the assay we grew cultures of the WT 17978 
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added 4-nitrophenyl myristate and determined the lipase activity by measuring the 
increase in absorbance at 415 nm over time. Prior to adding the lipase substrate, we 
measured the density of the cultures at 600 nm. This is an important step because 
many compounds, including known antibiotics, affect the growth of the bacteria resulting 
in false positives. While the move to the microtiter format required titration of IPTG to 
induce lipBA expression, a reproducible difference in lipase activity could be measured 
in the WT and mutant cultures. We further developed the lipase secretion assay in flat-
bottom 384-well plates using a MicromultiDrop liquid dispenser. As the conditions 
developed for the 96-well plates did not generate reproducible data in the 384-well 
format, we set up a systematic analysis to evaluate a variety of conditions to obtain the 
most consistent data. We varied growth media, culture volume, IPTG concentration, 
starting OD600 of the culture, growth temperature, length of growth, aeration, and finally, 
4-nitrophenyl myristate concentrations (Table 4.1). The experimental protocol that 
yielded the most consistent growth and reproducible lipase activity from well-to-well and 
plate-to-plate employed cultures grown in 10 µL MH broth (from a starting OD600 of 









Table 4.1. Optimization of assay conditions for development of a High-
Throughput Screen. 
Conditions Optimized Values Tested Final Assay 
Condition 
Plate format 96 well vs 384 well 384 well 
Start OD 0.005, 0.025, 0.001, 0.0005 0.005 
Media LB vs Mueller-Hinton (MH) MH 
Volume  10, 15, 20, or 30 µL 10 µL 
Temperature  20°, 24° (RT), 30°, 37° RT 
Aeration   Shaking vs non-shaking Non-shaking 
Substrate Concentration 0.225, 0.45, 0.9, 1.8 mM 0.45 mM 
 
Pilot Screen 
Following optimization, we screened 6,400 pharmacologically active compounds 
as well as FDA-approved drugs from the following libraries available at the University of 
Michigan Center for Chemical Genomics: MS2400, Prestwick, LOPAC, BioFocus NCC, 
and Focused Collections. This pilot screen evaluated the strength of the assay before 
moving on to larger compound libraries. Each 384-well plate contained 320 sample 
wells, 32 positive control wells, and 32 negative control wells. As the ultimate goal of the 
HTS is to identify T2SS inhibitors, the T2S mutant, 17978ΔgspD/plipBA served as our 
positive control, and 17978/plipBA served as the negative control. Both negative and 
positive controls were cultured in the presence of 0.5% DMSO, whereby the sample 
wells containing 17978/plipBA received the compounds resuspended in DMSO yielding 
a 0.5% final DMSO concentration. Following growth, the absorbance at 600 nm was 
measured for the cultures in each well. The average OD600 for the negative and positive 
controls were 0.21 ± 0.02 and 0.19 ± 0.02, respectively. The lipase substrate was then 
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added, and the absorbance at 415 nm was measured over a period of 20 min at 
ambient temperature. The pilot screen yielded a z-factor of 0.65 [z’ = 1-(3*(σp + σn)/(|µp-
µn|))](204) (Figure 4.4A) and coefficient of variation (CV, CV=σ/µ) of 0.03 and 0.07 for 
the negative and positive controls, respectively. Initial active compounds were identified 
using statistical comparisons to positive and negative controls present on every plate. In 
the triage process, we selected compounds that resulted in all of the following: a 
reduction in lipase activity that was equal or greater than 3 SD of the negative control, a 
minimum cut-off at 30% inhibition of lipase activity and an OD600 value greater than 0.17 
(Figure 4.4). Implementing these criteria yielded 191 compounds (3% hit rate). From 
these, we removed 22 compounds that are known antibiotics and retested the 
remaining 169 compounds. 
Each compound was re-tested twice in a concentration-dependent manner using 
the original DMSO stock and covering two orders of magnitude. IC50 values were 
calculated. Forty-eight compounds gave IC50 values of <30 µM. Following removal of 
compounds that affected growth, 34 active compounds remained (0.5% hit rate). Fresh 
powder of these compounds was ordered and retested. Of these compounds, 21 were 
confirmed as active. The compounds with the lowest IC50 values are known lipase 
inhibitors, Orlistat and Ebelactone B, and therefore likely had a direct effect on the 
lipase activity itself. Orlistat, a pancreatic lipase inhibitor, was the most potent of the 
compounds tested with an IC50 of 40.6 nM (Figure 4.5A). The other compounds 
exhibited IC50s between 4.3 and 27 µM (Table 4.2). The titration curves of Orlistat 
(Figure 4.5A) and Oxyclozanide (Figure 4.5B) are shown as examples. Of note, 
compounds with low IC50 values included tricyclic antidepressants that are known to act 
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as serotonin-norepinephrine re-uptake inhibitors. While these latter compounds may act 
on the secretion system, it is possible they also bind directly to the lipase via their 
hydrophobic rings. Our proof-of-concept pilot screen with z’=0.65 and CV of 0.03 and 
0.07 for the negative and positive controls, respectively, showed that our assay was 
reproducible and was capable of identifying compounds that result in a statistically 
significant reduction in lipase activity. However, the identification of compounds that are 
known lipase inhibitors emphasized the importance of developing counter screens and 
other follow-up assays to remove false positives and to assure specificity to identify 


















Figure 4.4. Demonstrating the feasibility of the 
lipase assay for high-throughput screen. A.  
One sample plate from the pilot screen showing 
the OD415 values for the positive (red) and 
negative (blue) controls. The z-factor for the  
entire pilot assay was calculated using  1-(3*(σp + 
σn)/(|µp-µn|)) where σ is the standard deviation and 
µ is the mean. B. The results for 6400 compounds 
tested in the pilot screen. A single sample plate is 
highlighted in the inset. All samples below the red 
line (3 SD from negative controls) were taken into 
consideration. The compound Orlistat, indicated 
by the circle, represents a hit in the primary 






Figure 4.5. Titrations of compounds and the corresponding IC50.  A. Titration of Orlistat, a pancreatic 
lipase inhibitor identified in the primary screen. Increasing amounts of Orlistat was included during growth 
of 17978/plipBA. After overnight incubation in 96-well plates, the substrate 4-nitrophenyl myristate was 
added, and the lipase activity was measured. Values have been normalized to OD600 of culture. n=3, 
bars represent standard deviation from the mean. B. Titration of Oxyclozanide, an antihelmintic that was 
identified in the primary screen. Lipase activity in the presence of Oxyclozanide was measured as above. 
Values have been normalized to OD600 of culture. n=3, bars represent standard deviation from the 
mean. 





Lipase Inhibitors  
     Ebelactone B (n=2) 4.3 
Anti-Depressants  
     Vivactil 10 
     Fluoxetine 10.5 
     Aventyl 14.5 
     Duloxetine 16 
     Norcyclobenzaprine 16 
     Maprotiline  16 
     Desiprimine 16.5 
     Lofepramine 21 
     Sertraline 23.5 
Other  
     Perhexiline Maleate 4.7 
     Febuxostat 8 
     Alfuzosin 11 
     Stattic 12.5 
     Fendiline  13 
     Tomoxetine 14.5 
     Indatraline 27 
 
IC50=40.6 nM IC50=19.7 µM 





















































As the most potent compounds identified in our pilot screen described above 
represented lipase inhibitors, we developed a screen to eliminate these types of 
compounds. In this counter screen, the bacterial cultures were not grown in the 
presence of compounds. Instead, a large batch of 17978p/lipBA culture was grown 
without compounds, and, following removal of cells, the cell-free culture supernatant 
containing the lipase was distributed in 384-well plates and incubated with the 
compounds, thus allowing us to identify compounds that inhibit the lipase itself. 
Following optimization, we identified the following conditions for the counter screen: 1) 
grow 17978p/lipBA with 50 µM IPTG for 16 h and remove cells by centrifugation; 2) 
dilute the supernatant 1:10 and add 10 µL to 384-well plates containing compounds; 3) 
add 10 µL 4-nitrophenyl myristate at 0.45 mM, incubate 10 min, and measure the 
change in absorbance at 415 nm.  
To eliminate compounds that interfere with plasmid-encoded lipBA expression, 
an additional counter screen was developed. For this purpose, we used the same 
plasmid backbone as plipBA but replaced the lipBA gene with the gfp gene, which 
codes for Green Fluorescent Protein (pgfp). After introducing this plasmid into the WT 
17978 strain (17978/pgfp) and without lysing the cells, reproducible GFP fluorescence 
was significantly higher than the fluorescence detected for 17978 with the vector alone 
negative control (17978/p) (Figure 4.6). We optimized the conditions and applied them 
in the following counter screen: cultures were grown in 10 µL MH from a starting OD600 
of 0.005 with 75 µM IPTG in a humid chamber at 24°C without shaking for 16 h and 
using 17978/pgfp and 17978/p as negative and positive controls, respectively. For this 
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counter screen, the compounds would be added to the cultures at the start of growth, 
with the fluorescence measured after growth. Any compound that is positive in both the 
primary screen and this counter screen is likely targeting expression of the plasmid-
encoded lipase and should be removed from the pool of potential hits. 
 
Figure 4.6. Detection of GFP fluorescence. Strains of 17978/p and 17978/pgfp were grown overnight in 
the presence of IPTG to induce the expression of GFP. After growth, fluorescence of intact cells of each 
strain was measured at  485 nm excitation, 520 nm emission and normalized to the OD=600 of the 
cultures. n=3, *** p<0.001 by Student t-test. 
Twenty-one compounds that had responded in a concentration-dependent 
manner in the primary HTS and then confirmed when using fresh powders were 
subjected to the lipase inhibitor and GFP counter screens. All of these compounds were 
identified as either lipase inhibitors (n=18; Table 4.2 and Figure 4.5A) or inhibitors of 
lipBA expression from the plasmid (n=4; representative compound shown in Figure 
4.5B), highlighting the necessity of utilizing counter screens before pursuing detailed 
characterization of false positives. 
As we move forward to screen larger libraries to identify T2SS inhibitors, our 






















compounds from the primary HTS (step 1) will be delivered in triplicate to three different 
sets of 384-well plates using the original DMSO stock solutions (step 2). The first set of 
plates will represent a repetition of the primary screen. The second and third sets of 
plates will be used to counter screen for compounds that inhibit lipase activity or 
plasmid-borne gene expression, respectively (Figure 4.7). Compounds that are positive 
in the counter screens will be eliminated from further consideration, and the remaining 
compounds will be tested for their ability to prevent secretion over a range of 
concentrations (step 3). Fresh compounds will be reordered and tested (steps 4 and 5). 
Active compounds will then be analyzed for inhibition of secretion in additional A. 
baumannii strains, as ideal T2SS inhibitors should be active against the T2SS of all the 
A. baumannii isolates regardless of antibiotic resistance phenotype.  
We have begun to test lipase activity of other strains of A. baumannii that were 
isolated from different body sites, are resistant to different antibiotics and produce 
different amounts of biofilm (Figure 4.8). While we have previously shown that detection 
of lipase activity in the culture supernatant of ATCC 17978 grown in LB in the absence 
of lipids requires overexpression of LipA from a plasmid, other strains display lipase 
activity without the need for LipA overexpression (Figure 4.8). The difference in lipase 
activity among the strains may be due to differences in expression of lipA as well as the 
presence of other lipases such as LipH which may or may not be dependent on the 
T2SS for extracellular secretion. We constructed a T2SS mutant of one of the strains, 
AB031 (to be described elsewhere). This ΔgspD mutant had a statistically significant 
reduction in lipase activity compared to the WT AB031 strain, indicating that a 
detectable portion of the lipase activity stems from a T2SS-dependent lipase(s) (Figure 
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4.8). This strain, as well as any others we may find as we continue to screen A. 
baumannii isolates for extracellular lipase activity, may be used to further analyze active 
hits to help determine which compounds to pursue. Analysis of additional strains such 
as AB0057 and AB5075 that show low lipase activity, however, will likely involve 
plasmid-expression of LipA.  
 





Figure 4.8. T2S lipase activity of other A. baumannii strains. The lipase substrate 4-nitrophenyl 
myristate was added to overnight cultures of the indicated A. baumannii strains, and the lipase activity 
was measured. Values were normalized to the OD600 readings of each culture. Bars show standard 
deviations from the means, n=3.  *  p<0.05 by Student t-test.   
Discussion 
Here, we provide additional information on the T2SS in A. baumannii. In addition 
to supporting colonization, in part through the secretion of LipA, we show that the T2SS 
also contributes to serum resistance, as there is a ≥100-fold reduction in recoverable 
CFUs of ATCC 17978 ΔgspD mutant following exposure to human complement. The 
mechanism by which the T2SS protects A. baumannii from human complement is not 
known but published reports have shown that A. baumannii expresses secreted and 
surface-associated proteins that contribute to serum resistance, and it is possible that 
they use the T2SS for outer membrane translocation. The serine protease PKF is 
produced with an N-terminal signal peptide, a prerequisite for T2S, and CipA, another 




































































































pullulanase and SslE, are examples of surface-associated T2S substrates, and CipA 
may similarly localize to the cell surface via the T2SS (79, 205). While PKF is a member 
of the HtrA family of chaperone-proteases that refold or degrade misfolded proteins in 
the periplasmic compartment (206), it is detected in A. baumannii culture supernatant, 
possibly due to its secretion via the T2SS.  
The reduced in vivo fitness in mouse models of bacteremia (174) and pneumonia 
(176) and the increased sensitivity to complement killing of T2SS deficient A. baumannii 
(Figure 4.2) suggest that the T2SS plays an important part during infection through the 
action of specific T2S substrates, and thus shows great potential for therapeutic 
targeting. GspD may be an especially promising target, as it forms a gated channel in 
the outer membrane through which transport occurs. Potential drugs, therefore, would 
not need to penetrate membranes to reach their target and would not be subject to the 
effect of drug efflux pumps. This latter point may be of particular interest in the 
treatment of bacteremic A. baumannii, as the expression of several efflux pumps are 
upregulated when A. baumannii is cultured in human serum (207).  
Here, we describe the development and optimization of a HTS to identify small 
molecule inhibitors of the T2SS in A. baumannii. Using a previously published assay, 
we developed, optimized, and tested a high-throughput assay on a small library of 
pharmacologically active compounds. Our assay demonstrated little fluctuations within 
controls and showed an acceptable dynamic range between our positive and negative 
controls yielding a z-factor of 0.65. Our proof-of-concept pilot study also indicated that 
the assay is simple, straightforward, reproducible, robust, and specific as it identified all 
four lipase inhibitors and seven tricyclic antidepressants present among the 6,400 
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compounds tested. In addition, the pilot study underscored the importance of including 
counter screens to reduce the number of false-positives that target substrates, but not 
the T2SS. We feel confident that our primary lipase screen and counter screens have 
been sufficiently optimized to be used to screen larger libraries of compounds.  
Other studies have implemented similar approaches for the identification of 
secretion inhibitors with notable differences. The first screen developed, validated and 
used a gain-of-signal screen to identify inhibitors of SecA, an essential component of 
the Sec export pathway in Pseudomonas aeruginosa (208). No inhibitors were identified 
that directly interfere with the Sec pathway, as the transport of the periplasmic enzyme 
β-lactamase was not affected. However, following application of secondary assays, a 
set of compounds was found to reduce the extracellular activity of T2SS substrates, 
although they had no effect on the secreted substrates themselves, suggesting that the 
compounds inhibit their secretion (208). Our screen differs from the Sec screen in that 
we use a T2SS mutant as our positive control, thus increasing the specificity of our 
assay. In addition, our screen includes high-throughput counter screens that remove 
false positives early in the triage process. The screen developed and validated by Tran 
et al. utilized the plant pathogen Dickeya dadantii  (209). Similar to our screen, the 
authors measured OD600 after growth to detect antibiotics and used the activity of a T2S 
substrate to measure T2SS function. As with the Moir et al. screen, the Tran et al. 
screen did not utilize counter screens in the high-throughput screening process (208, 
209). What is apparent in all three studies is that identified compounds have to be 
subjected to many additional tests before they can be verified as true T2SS inhibitors. 
Among others, the presence of active compounds should cause an accumulation of T2S 
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substrates in the periplasmic compartment. Once we implement our screen for the 
identification of T2SS inhibitors in A. baumannii, it will be advantageous to compare any 
active compounds to the compounds discovered in these two other screens to search 
for similarities amongst the compounds.  
While the primary goal of this pilot screen was to develop a HTS regimen to 
identify compounds to target the T2SS, our data indicate that our dual screen combined 
with counter screens also have the potential to identify compounds with antibiotic 
properties and reveal new targets for known pharmacological compounds already in 
use. For example, we discovered that the tricyclic antidepressants efficiently inhibit A. 
baumannii LipA. Less surprising was the finding that the pancreatic lipase inhibitors 
Orlistat and Ebelactone B efficiently inhibit LipA activity. However, as our previous study 
has shown that LipA enhances A. baumannii colonization (174) and that A. baumannii 
secretes several lipolytic enzymes including LipH and LipAN that may also support in 
vivo survival of A. baumannii (175, 176), a lipase inhibitor has potential for therapeutic 
use. Along with T2SS inhibitors, our HTS may also identify inhibitors of LipB, the 
chaperone for both LipA and another T2S substrate, LipH (175), which may also be 
developed for therapeutic intervention. 
While a T2SS inhibitor for therapeutic purposes is our ultimate goal, we are also 
interested in pursuing small molecules that can be used as tools to study T2S in 
multidrug resistant strains as they are often genetically intractable and very difficult to 
study systematically. Therefore, development of chemical probes to advance virulence 
studies of these antibiotic resistant isolates is also critically important.   
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Characteristics Source or Study 
Strain   
   17978 WT for this study ATCC 
   17978ΔgspD T2S mutant (174) 
   17978ΔgspN  (174) 
   17978ΔlipA  (174) 
   AB031 Clinical strain (177) 
   AB031 ΔgspD T2S mutant Waack et al., in preparation. 
   AB 0057 Clinical strain, tetR, chlR, trimR, carbR (168) 
   AB 5075 Clinical strain, tetR, rifR, carbR, trimR (169) 
   P020 Clinical strain, cefR (210) 
   C038 Clinical strain, cefR (210) 
   C058 Clinical strain, merR, aztR, cefR, cipR, 
levR, imiR 
(210) 
   C076 Clinical strain, aztR, cefR, cipR, levR, 
trimR 
(210) 
   P084 Clinical strain, merR, aztR, cefR, cipR, 
levR, imiR 
(210) 
   C097 Clinical strain (210) 
   P102 Clinical strain, merR, aztR, cefR, cipR, 
levR, imiR  
(210) 
   P143 Clinical strain, aztR, cefR (210) 
Plasmid   
   pMMB67EH Low copy vector (Apr) (163) 
   plipBA pMMB67EH-lipBA (Apr) (174) 
   pgfp pMMB67EH-gfp (Apr) (211) 
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Chapter V:  
Discussion 
Due to the escalating prevalence of antibiotic resistant infections caused by A. 
baumannii, this nosocomial pathogen is receiving increased attention. While much 
research has focused on the mechanisms of antibiotic resistance, there is a growing 
interest in the mechanisms of A. bauamanii pathogenesis. Like many opportunistic 
pathogens, a single virulence factor, such as a toxin, does not appear to cause all or 
even the majority of disease symptoms. Instead, A. baumannii seems to thrive due to a 
variety of mechanisms, some of which were described in Chapter I. The goal of my 
dissertation research was to increase our understanding of the pathogenesis of A. 
baumannii by investigating the contributions by the T2SS.  
Discovery of the T2SS in A. baumannii 
In Chapter II, I presented our study that highlighted the presence of a functional 
T2SS in A. baumannii which is notable due to the unique organization of the T2S genes 
in multiple operons instead of the typical one or two (Figure 2.1). We demonstrated that 
wild-type A. baumannii but not a T2SS mutant is able to grow on lipid agar (Figure 2.2). 
In addition, we identified a lipase, LipA, which is responsible for this growth. Both a LipA 
mutant and a T2SS mutant were outcompeted by the isogenic wild-type strain when 
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colonizing either the murine liver or the spleen following intravenous inoculation (Figure 
2.6). This suggests that both the T2SS and LipA promote A. baumannii colonization in 
the bacteremia model. 
One interesting avenue of research that stems from this study would be to 
understand the unique genetic organization of the T2SS genes in A. baumannii (Figure 
2.1). As mentioned in Chapter II, the genes for the T2SS are generally encoded in one 
or two operons while the T2SS genes in A. baumannii are spread over several operons 
throughout the genome. This raises the question of what drove the scattered genetic 
organization of A. baumannii. Were the genes originally in one or two operons like other 
T2SS systems but have separated into multiple small operons over time? Alternatively, 
did the genes integrate into the genome in different places at different times when the 
bacterium acquired the T2SS genes from other bacteria?  I believe the first hypothesis 
or some version of it is likely the correct explanation. There do not appear to be any 
insertion sequences near the T2SS genes that would indicate an insertion of those 
genes. In addition, obtaining the genes in a piecemeal manner does not seem 
advantageous for the bacterium, since at a minimum, all the core genes (gspC-M and 
pilD) are needed to gain any known advantage for retaining any of the genes. Currently, 
all sequenced A. baumannii strains possess all the T2SS core genes, which are highly 
homologous, an observation that indicates the full set of genes were acquired before 
the strains diverged from each other. Future work could take a bioinformatics approach 
to address the questions: What does the organization of the T2SS genes look like in the 
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Acinetobacter genus? Do any Acinetobacter species lack the genes or contain only a 
subset of the genes?  
In addition to the questions raised by the genetic organization of the T2SS genes 
in A. baumannii, our first study also leaves unanswered questions regarding the lipase 
LipA. We hypothesized that LipA might be utilized for nutrient acquisition, interference 
with host cell signaling, or for an unknown function. Interestingly, A. baumannii secretes 
several lipases, including a phospholipase via the T2SS (174-176). The lipases may 
work together to acquire nutrients, possibly by targeting host cell membranes. It may be 
surprising that loss of a single secreted substrate reduced the ability of the lipA mutant 
strain to compete with the wild-type strain (Figure 2.6). One would think that the mutant 
strain would benefit from the activity of the lipase secreted by the wild-type strain as 
long as it is in proximity at high cell density. This would be the case with either nutrient 
acquisition or interference with host cell signaling. If the lipase is breaking down long-
chain fatty acids, the bacterium closest to the breakdown product would benefit, but it 
would not necessarily be the same bacterium that secreted the lipase. The same would 
be true if the lipase interferes with host cell signaling. However, at low cell density the 
wild-type and mutant cells are likely present in clonal populations in which the mutant 
cells will not be in close contact with wild-type cells. It is also possible that the wild-type 
and mutant cells are not occupying the same location within the organs. Both strains 
must survive in the blood stream before colonizing either the spleen or the liver. If the 
strains do not arrive in the same area of the organs, it would explain why the lipA 
mutant is not able to benefit from the LipA secreted from the wild-type strain. 
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The T2SS, CpaA, and fXII  
In Chapter III, we investigated the function of another T2S substrate, CpaA, in a 
different strain of A. baumannii, AB031. Previous work by other groups has shown that 
the metalloprotease CpaA increases the time to form blood clots as measured by the 
aPTT assay(177). In addition, CpaA is T2-secreted and requires a putative chaperone, 
CpaB for folding and/or secretion(175). We have expanded on these two studies and 
shown that a ΔcpaA mutant is less competitive than a wild-type strain in a murine model 
for bacteremia (Figure 3.3). In addition, we demonstrated that CpaA cleaves the clotting 
factor fXII in a heavily glycosylated proline-rich domain between Pro308 and Thr309. By 
deglycosylating fXII before incubation with CpaA, we showed that the glycosylation of 
fXII is necessary for cleavage by CpaA but not for activity of fXII.  
The requirement of fXII glycosylation for cleavage by CpaA is particularly 
interesting, especially as there are individuals without a glycosylated T309 due to a 
mutation. As mentioned in Chapter III, the T309K and T309R mutations are found in 
patients with hereditary angioedema Type III. Patients with other forms of hereditary 
angioedema have mutations in C1-inhibitor, which represses the cleavage and 
autoactivation of fXII (212). Thus, these patients have an unchecked activation of the 
kallikrein/kinin system. Patients with hereditary angioedema Type III have the same 
symptoms and increased activation of the kallikrein/kinin pathway but normal C1 
inhibitor function and an overactive fXII caused by the mutations. These mutations are 
autosomal dominant and, although rare, can be tracked through families. Are the 
mutations protective in some manner and the increased activation of fXII and potentially 
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life-threatening outcome reasonable side effects? Perhaps the answer lies in its host’s 
ability to survive infections from bacteria such as A. baumannii. The normal host 
response relies on the innate immune system and can include trapping the bacterium in 
a clot to prevent dissemination and present an easy target for immune cells. To 
circumvent this natural defense mechanism, we postulate that A. baumannii secretes 
CpaA to prevent or prolong the formation of clots. Perhaps host fXII mutations are a 
way to counter act this virulence strategy. Conversely, it is possible that there is no 
advantage to having these mutations for survival but instead there has not been 
sufficient negative selection to remove the fXII mutations from the gene pool.  
There are several ways to determine which hypothesis is the correct one. From 
an epidemiological standpoint, we could compare the rates of infection of A. baumannii 
in individuals with hereditary angioedema type III versus healthy individuals. This 
approach may be problematic due the small number of individuals with this condition. 
Ideally, we would also compare the different types of hereditary angioedema and 
determine if the rate of infection changes depending on which mutation a patient has. 
Another possible method is to perform mouse studies, although this approach has its 
own problems. As shown in Figure 3.4, CpaA increased the clotting time for both human 
and murine plasma, but was less potent in the murine plasma. This pattern may indicate 
substrate specificity, since murine fXII and human fXII are only 70% identical. In 
addition, the site of CpaA cleavage in human and murine fXII is not identical (Figure 




Figure 5.1. Amino acid alignment of murine fXII and human fXII.  The highlighted residue is the O-
linked glycosylated T309 that is important for CpaA cleavage. The underlined sequence is the sequence 
identified by N-terminal sequencing in chapter three. Note the lack of homology between the human and 
mouse fXII in that region.  
During our study, we expressed recombinant histidine-tagged wild-type, T309K, 
and T309R fXII in a cell line derived from human kidney. Although we visualized 
expression of all three proteins via Western blotting and purified each by cobalt affinity 
chromatography (not shown), we were unable to determine cleavage of any of them by 
CpaA, including the wild-type protein. Additionally, we noticed that none of the 
FA12_MOUSE      MTALLFLGSLLMSLDLTLSAPPWKDSKKFKDAPDGPTVVLTVDGRLCHFPFQYHRQLHHK   
                M ALL LG LL+SL+ TLS PPW+  K+ K   +  TVVLTV G  CHFPFQYHRQL+HK 
FA12_HUMAN      MRALLLLGFLLVSLESTLSIPPWEAPKEHKYKAEEHTVVLTVTGEPCHFPFQYHRQLYHK  
 
FA12_MOUSE      CIHKRRPGSRPWCATTPNFDEDQQWGYCLEPKKVKDHCSKHNPCHKGGTCINTPNGPHCL 
                C HK RPG +PWCATTPNFD+DQ+WGYCLEPKKVKDHCSKH+PC KGGTC+N P+GPHCL 
FA12_HUMAN      CTHKGRPGPQPWCATTPNFDQDQRWGYCLEPKKVKDHCSKHSPCQKGGTCVNMPSGPHCL  
 
FA12_MOUSE      CPEHLTGKHCQKEKCFEPQLLKFFHENELWFRTGPGGVARCECKGSEAHCKPVASQACSI 
                CP+HLTG HCQKEKCFEPQLL+FFH+NE+W+RT    VARC+CKG +AHC+ +ASQAC   
FA12_HUMAN      CPQHLTGNHCQKEKCFEPQLLRFFHKNEIWYRTEQAAVARCQCKGPDAHCQRLASQACRT  
 
FA12_MOUSE      NPCLNGGSCLLVEDHPLCRCPTGYTGYFCDLDLWATCYEGRGLSYRGQAGTTQSGAPCQR  
                NPCL+GG CL VE H LC CP GYTG FCD+D  A+CY+GRGLSYRG A TT SGAPCQ  
FA12_HUMAN      NPCLHGGRCLEVEGHRLCHCPVGYTGAFCDVDTKASCYDGRGLSYRGLARTTLSGAPCQP 
                                                               
FA12_MOUSE      WTVEATYRNMTEKQALSWGLGHHAFCRNPDNDTRPWCFVWSGDRLSWDYCGLEQCQTPTF           
                W  EATYRN+T +QA +WGLG HAFCRNPDND RPWCFV + DRLSW+YC L QCQTPT  
FA12_HUMAN      WASEATYRNVTAEQARNWGLGGHAFCRNPDNDIRPWCFVLNRDRLSWEYCDLAQCQTPTQ 
                                                              
FA12_MOUSE     APLVVPES----------QEESPSQAPSLSHAPNDST--------DHQTSLSKTNTMGCG 
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FA12_HUMAN      AAPPTPVSPRLHVPLMPAQPAPPKPQPTTRTPPQSQTPGALPAKREQPPSLTRNGPLSCG 
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FA12_MOUSE      EELTVVLGQDRHNQSCEWCQTLAVRSYRLHEGFSSITYQHDLALLRLQESKTNSCAILSP  
                E+LTVVLGQ+R N SCE CQTLAVRSYRLHE FS ++YQHDLALLRLQE    SCA+LSP 
FA12_HUMAN      EDLTVVLGQERRNHSCEPCQTLAVRSYRLHEAFSPVSYQHDLALLRLQEDADGSCALLSP 
                                                               
FA12_MOUSE      HVQPVCLPSGAAPPSETVLCEVAGWGHQFEGAEEYSTFLQEAQVPFIALDRCSNSNVHGD  
                +VQPVCLPSGAA PSET LC+VAGWGHQFEGAEEY++FLQEAQVPF++L+RCS  +VHG  
FA12_HUMAN      YVQPVCLPSGAARPSETTLCQVAGWGHQFEGAEEYASFLQEAQVPFLSLERCSAPDVHGS 
                                                               
FA12_MOUSE      AILPGMLCAGFLEGGTDACQGDSGGPLVCEEGTAEHQLTLRGVISWGSGCGDRNKPGVYT  
                +ILPGMLCAGFLEGGTDACQGDSGGPLVCE+  AE +LTL+G+ISWGSGCGDRNKPGVYT 
FA12_HUMAN      SILPGMLCAGFLEGGTDACQGDSGGPLVCEDQAAERRLTLQGIISWGSGCGDRNKPGVYT 
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                DVA YLAWI++H  S 
FA12_HUMAN      DVAYYLAWIREHTVS  
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recombinant proteins were detected with a monoclonal fXII antibody, although they 
were efficiently recognized by polyclonal fXII antibodies, suggesting that these variants 
may differ from plasma-derived fXII in posttranslational modification such as 
glycosylation (data not shown). We are attempting other methods to produce 
recombinant fXII that has the correct fXII glycosylation needed for recognition by CpaA. 
Alternatively, we could procure plasma from patients with hereditary angioedema type 
III for analysis. 
CpaA cleaves fXII (Figure 3.7A) as well as fV (Figure 3.7B and reference (177)), 
even though only the cleavage of fXII results in inactivation. Do these two proteins 
share a similar motif or glycosylation pattern that CpaA recognizes? One way to begin 
to answer this question is to cleave fV with CpaA and then to submit the cleaved 
products for N-terminal sequencing. This strategy would determine the cleavage site in 
fV. If this cleavage site also has O-linked glycosylated residues, it could explain why fV 
is also cleaved by CpaA, although the physiological ramifications, if any, would be 
unknown.  
Another lingering question is what is the physiological consequence of CpaA 
mediated cleavage of fXII? Under normal circumstances, fXII is cleaved when activated 
(Figure 5.2, blue triangle), but the domains are still connected via a cysteine bond 
(labeled as A in Figure 5.2). This cysteine bond is cleaved and the two domains are 
separated. CpaA’s cleavage site is not located within the catalytically active domain 
(Figure 5.3, enlarged inset) and would, theoretically, have no effect on the fXII activity. 
However, cleavage of fXII separates the heavy chain from the catalytic domain 
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prematurely and may thus prevent surface binding, an important function of the heavy 
chain, and thus autoactivation of fXII.  
 
Figure 5.2. Cringle diagram of fXII. Amino acids colored blue encode a surface binding site. Green 
amino acids comprise a zinc-binding domain. The catalytic residues are represented by red amino acids. 
Cysteine bonds are depicted by a straight line. The letter A indicates the cysteine bond that connects the 
heavy chain and catalytic domain after activation. The blue triangle represents the cleavage site for fXII 
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Figure 5.3. Cleavage Site of CpaA. The cleavage site of CpaA (shown by green arrow) is shown in the 
enlarged view of the fXII sequence. CpaA cleaves before T309, indicated by the green amino acid. The 
site of cleavage for activated fXII is shown by the blue arrow, and A indicates the cysteine bond which 
connects the heavy and catalytic domains. Figure modified from Colman and Schmaier (213). 
Future work should examine whether the T309K and T309R mutations in fXII 
prevent CpaA mediated cleavage, investigate the specificity of CpaA, and determine the 
physiological implications of CpaA cleavage of fXII.  
Targeting the T2SS 
 My last project attacked the A. baumannii pathogenesis conundrum from a 
different angle. While both chapters II and III contribute to our understanding of the role 
of the T2SS in pathogenesis by examining the function of particular secreted substrates, 
chapter IV aimed to find inhibitors of the T2SS. We know from both our work and that of 
others that the T2SS is required for colonization of A. baumannii and the closely related 
A. nosocomialis in both a bacteremia and pneumonia model in mice (174, 176) as well 
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the A. baumannii strain ATCC 17978 requires a T2SS but not the secreted lipase LipA 
to withstand complement-mediated killing (Figure 4.2). This pattern suggests that the 
T2SS secretes many substrates which could promote colonization and survival. The 
potential to prevent secretion of many substrates as well as its multitude of potential 
drug targets makes the T2SS a promising therapeutic target. To this end, we 
developed, optimized, and validated a high-throughput lipase assay to identify T2SS 
inhibitors. In addition, we developed and optimized two counter screens to minimize 
potential false positives. We showed that a robust, specific, and sensitive assay with 
counter screens is now ready to be utilized to test larger libraries of compounds. 
 Following compound library screening, our list of potential inhibitors will be 
greatly reduced when we move forward with additional specificity assays. For example, 
we can use other A. baumannii strains with different antibiotic resistance patterns to test 
for lipase activity and only proceed with compounds that have an effect on several 
strains. To allay concerns that the inhibitor only inactivates lipase and/or its chaperone, 
we will use the clotting assay described in Chapter III to test the compounds for 
interference with CpaA secretion. In addition, we will also perform tests designed to 
verify that our compounds do indeed inhibit the T2SS. For example, when the T2SS is 
no longer active, the substrates accumulate in the periplasm(126). The same 
phenomena should occur with LipA and CpaA as well as other T2S substrates after 
treatment of the bacterium with the compounds. 
 Once we are confident that the compounds indeed target the T2SS, we can 
move our compounds forward. By utilizing the resources available at the University of 
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Michigan, we can perform structure-activity relationship analysis to develop and 
produce compound(s) with higher activity. In addition, studies will investigate the 
mechanism of inhibition and identify the precise target of the compound(s). Any 
promising compounds will also be tested for pharmacological properties and efficacy in 
vivo. Furthermore, even compounds that may not be useful as a drug could be utilized 
as research tools. For example, compounds could be used to characterize the structure 
and function of the T2SS. Many strains of A. baumannii are resistant to a wide variety of 
antibiotics, and it would be difficult to genetically manipulate these strains to construct 
T2SS mutants using canonical cloning techniques. However, by using a compound to 
inhibit the T2SS in vitro, we could gain insight into the role of the T2SS in these strains. 
Concluding Remarks 
My dissertation has presented novel work on the T2SS and its role in the 
pathogenesis of A. baumannii. We have demonstrated the activity of the T2SS in A. 
baumannii as well as probed the activity of its two substrates, LipA and CpaA. We have 
shown that the T2SS as well as LipA and CpaA support A. baumannii colonization in a 
murine bacteremia model. We characterized CpaA and showed that it cleaves fXII and 
demonstrated that O-linked glycosylated residue(s) are necessary for this cleavage. 
Furthermore, we developed, optimized, and validated a high-throughput screening 
assay to identify small molecule inhibitors of the T2SS. This assay has been proven to 
be robust, sensitive, and reliable. Taken together, my dissertation has highlighted the 
importance of the T2SS in the pathogenesis of a highly concerning hospital acquired 
pathogen and made progress toward the isolation of potential therapeutic agents to 
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